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p53 family membersAt the end of the last century, the discovery of p53 protein 
homologues named p63 and p73, engendered the concept of a new family of p53-like 
transcription factors. The research focus expanded from a single protein named the “ 
guardian of the genome” to a family of transcription factors that likely have distinct 
roles through the diverse collection of genes they regulate. p53 was discovered 25 
years ago as a protein interacting with the oncogenic T antigen from SV40 virus. P53 
transcription factor is the product of a pivotal tumor-suppressor gene, whose 
inactivaction is the most frequent single gene event in human cancer, and germline 
mutation in human p53 gene are cause of enhanced risk of developing cancer ( Li-
Fraumeni syndrome) .  The p53 gene encodes a protein with a central DNA binding 
domain, flanked by an N-terminal transactivation domain, and a C-terminal  
tetramerization domain ( Levine et al;1997). The active form of p53 is a tetramer and, 
consistent with its tetrameric state, p53 binds DNA sites that contain four repeats of 
the pentamer sequence motif 5’-Pu-Pu-Pu-C-A/T-3’. Until now, the p53 gene 
structure was considerate much simpler, with only one promoter and transcribing 
three mRNA splicing variants encoding, respectively, full-length p53, p53i9 ( Flaman 
et al;1996), and ∆40p53 ( Courtois et al.2002; Ghosh et al.2004). Recent studies have 
proposed for the p53 gene a structure more complex  than has been previously 
thought. The p53 gene, as the other two family members p63 and p73, contains two 
promoters and can generate six different mRNAs, that encode at least six p53 
isoforms ( Bourdon et al. 2005). P53 isoforms are expressed in several normal  
human tissue. The functions of p53 are primarily the regulation of cell cycle 
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checkpoints, apoptosis, and genome stability. A substantial number of genes, 
involved in cell cycle arrest or in induction of apoptosis, are activated by p53. These 
include MDM2, p21WAF, GADD45, bax and IGF-BP3. p53 has also been reported 
to negatively regulate the transcription of a number of genes such as presenilin 1, 
topoisomerase IIα, bcl2 and hsp70.  The transcriptional activity and stability of p53 
are highly regulated by posttranslational mechanisms involving protein-protein 
interaction, phosphorylation, acetylation, ubiquitination, and sumoylation.  
MDM2 is an ubiquitin ligase and a p53 transcriptional target; it binds to the p53 
transactivation domain, and inhibits its transcriptional activity. MDM2 shuttles p53 
out of the nucleus targeting the protein for ubiquitin-mediated proteolysis ( 
Vogelstein et al. 2000).  MDM2, thus, is assumed to be the principale regulatorof p53 
protein levels. The p14ARF tumor suppressor protein, one of the alternative products 
of the INK4A locus, antagonizes MDM2 activity leading to p53 stabilization. Several 
mechanisms have been postulated to inactivate p53 such as amplification of MDM2 
gene, deletion of ARF gene, expression of some viral oncogenes that stimulates p53 
degradation or missense mutation in DNA binding domain that disrupt the DNA 
binding capability of p53.   
P63 and p73 are genes structurally related to p53. In fact, also p63 and p73 proteins 
contain an N-terminal transactivation domain, which shares 25% homology with N-
terminal part of p53, the DNA binding domain, which shares 65% of homology with 
the corresponding p53 domain, and the tetramerization domain, which shares 35% of 
homology with the oligomerization domain of p53. The p63 and p73 genes are 
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transcribed from two distinct promoters, giving rise to proteins that either contain ( 
TA isoforms) or lack ( ∆N isoforms) the N-terminal transactivating domain. In 
addition, both p63 and p73 genes, are subject to alternative splicing event that 
generate three ( α, β, γ )  and seven ( α, β, γ, δ, ε, ζ,η )  different C-termini 
respectively for p63 and p73 encoded proteins ( Yang and McKeon; 2002). The α 
isoforms contain a sterile α motif ( SAM ) and a transactivation inhibitory domain ( 
TID ). The SAM domain, which is absent in p53, is a protein-protein interaction 
domain also found in other developmentally important protein, such as several Eph 
receptor tyrosine kinase ( Schultz et al; 1997 ). 
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 Structure of both TP63 and major protein isotypes. TP63 uses several transcription initiation sites and extensive alternative
splicing, to generate different mRNA. Several protein domains can be distinguished; of these, the TA domains, the DBD, and
the OD domain are highly homologous to the corresponding domain in p53. The SAM domain and the TID are not contained
in the p53 protein. 
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The Transactivation inhibitory domain of p63 binds to the N-terminal TA domain 
masking residues that are important for transactivation ( Serber et al; 2002 ). In fact,  
p63 isoforms that contain the γ and β C-termini are associated with higher 
transactivation competency that ones with α terminus ( Shimada et al; 1999 ). The 
lack of TA domain in ∆Np63 isoforms suggest that they are transcriptionally 
competent. Since ∆Np63 isoforms retain the oligomerization and DNA binding 
domains, it is plausible that they act as dominant negative inhibitorsof p53 and TA-
containing p53 family members ( Yang et al;1998. Westfall et al; 2003) . Indeed, 
numerous studies show that co-expression of ∆Np63 with either TAp63, TAp73, or 
p53 has inhibitory effect on TAp63-mediated transcription. A plausible mechanism is 
the formation of transcriptionally inactive ∆N-TA heterotypic or  homotypic 
tetramers (composed of either all-TA or all-∆N monomers) that compete for the same 
DNA binding sites. Despite the well-documented role of ∆Np63 as a dominant 
negative transcriptional repressor, several studies have shown that ∆Np63 isoforms 
directly transactivated a set of genes including Hsp70 and p57Kip ( Beretta et al; 
2005; Wu et al; 2005; King et al; 2003 ). This is possible thanks to existence of two 
cryptic transactivation domains in ∆Np63 isoforms: a region encompassing the first 
26 N-terminal amino acids named TA2 domain and a prolin rich sequence 
corresponding to exon 11/12 present in p63 β and α isoforms ( Ghioni et al; 2002 ). 
Surveillance of cellular integrity might be achieved throught a network of these p53-
like tumor suppressors. This speculation was, further, fueled by the observation that 
the p73 gene is localized to chromosome 1p36.3, a region that is frequently lost in 
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neuroblastomas and in other types of cancers ( Kaghad et al; 1997; Takahashi et al; 
1998 ), while the p63 chromosomal location, 3q27-29, is deleted in some bladder 
cancers and amplified in some cervical, ovarian, lung , and squamous cell carcinoma 
( Yang et al; 1998 ) where ∆Np63 was the predominant isoform expressed at protein 
level ( Cui R et al; 2005). Moreover, both p73 and p63 can bind to p53 DNA-binding 
sites and activate transcription of genes that mediates cell cycle arrest  or apoptosis in 
vivo. Despite all this circumstantial evidence, however, only a very few mutation in 
p63 and in p73 have been found in human tumors, and a direct link to carcinogenesis 
similar to that for p53 has so far not established ( Ichimiya et al; 2001; Nomoto et al; 
1998 ). Moreover the analysis of p63 and p73 deficient mice and studies on human 
tumors  have often led to conflicting results with regards to its role in tumorigenesis ( 
Westfall et al; 2004; Flores et al; 2005; Keyes et al; 2006).  
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p63 knock-out and transgenic mouse models: toward a comprehension of p63 
physiological function. 
Target gene disruption studies in mice have established an important role for p63 in 
development and differentiation. Mice lacking p63 are born alive but have striking 
developmental defects. Their limbs are absent or truncated, defects that are caused by 
a failure of the apical ectodermal ridge ( AER ) to differentiate. 
 
 
 
The lack of a proper AER in p63 -/- limb 
to undergo growth and differentiation th
Mills et al; 1999 ). The skin of the p63 de
developmental stage: it lacks stratificat
markers .  
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p63-/- mice on postnatal day have hypoplastic upper and lower
jaws, and have no eyelids, whisker pads, skin and related
appendages, including vibrissae, pelage follicles and hair shaft.
Homozygous mutants lack distal components of the forelimb,
including the radius, carpals and digits, as well as all
components of the hindlimb.    
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 a)Defects in stratified epithelial differentiation in p63-deficient mice. p63-/- mice lacking
squamous stratification in the epidermis (top) and tongue epithelium (bottom) 
.b) Immunohistochemical staining with the 4A4 anti-p63 antibody, showing p63 protein
expression in the apical ectodermal ridge. The AER is absent in the p63-/-. , p63-deficient mice have striking and visible skin defects, in fact, they die 
a day of birth from dehydration. Structures dependent upon epidermal-
hymal interactions during embryonic development, such as hair follicles, teeth 
mmary glands, are also absent in p63 deficient mice. The surface of the skin is 
 by a single layer of flattened cells, without the spinosum, granulosum and 
 corneum. Two contrasting models have been advanced to explain the absence 
fied epithelia ( McKeon et al; 2004). One model posits that p63 is required for 
epithelial cells to commit to a stratified epithelial lineage during development 
et al; 1999). The second model argues that the primary defect resides not in 
uisition of stratified epithelial cell fate but rather in an inability of epidermal 
lls to sustain epidermal self-renewal ( Yang et al; 1999).  
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 Model for p63 in maintaining the proliferative capacity of epithelial progenitor cells. Stem cells in the basal layer of
stratified squamous epithelia express high levels of p63 and undergo asymmetric division to enable both selfrenewal
and progression to transient amplifying cells (TACs). TACs, which may express less p63, are also capable of limited
proliferation and self-renewal, but are ultimately destined for terminal differentiation. The absence of p63 results in the
failure to maintain a basal cell population, suggesting a requirement for p63 in the regenerative aspect of stem cell
division. he finding that p63 is specifically expressed in epithelial cells that have adopted an 
pidermal fate suggested that p63 is involved in development of the embryonic basal 
ayer, the first layer of embryonic epidermis.  
he epidermis is an example of stratified epithelium. It functions as a barrier 
rotecting the organism from dehydration, mechanical trauma, and microbial insults. 
his barrier function is established during embryogenesis through a complex and 
ightly controlled stratification program. The epidermis, the outermost component of 
he skin, is the primary barrier that protects the body from dehydration, mechanical 
rauma, and microbial insults. The epidermis is separated from the underlying dermis 
y the basement membrane, which consists of proteins secreted by epidermal 
eratinocytes and by dermal fibroblasts (McMillan et al. 2003). The two 
ompartments of the skin, the dermis and the epidermis, function cooperatively and 
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together are responsible for the development of epidermal appendages, including hair 
follicles and mammary glands (Chuong et al; 1998). Therefore, a failure to properly 
develop either the dermis or the epidermis may result in defects in appendage 
development. This is, for example, illustrated by ectodermal dysplasias, in which 
primary defects in epidermal development are the cause of subsequent defects in 
epidermal appendages (Koster and Roop; 2004; Priolo et al; 2000). 
The barrier function of the epidermis is established during embryogenesis and is the 
result of a complex and precisely coordinated stratification program. In mice, the 
execution of this program occurs in a period of approximately 10 days, between E8.5 
and E18.5, and initiates when cells of the surface ectoderm commit to an epidermal 
fate. 
 
 
 
 
 15(a) Schematic illustrating epidermal
morphogenesis. During epidermal
morphogenesis, the single-layered surface
ectoderm that initially covers the developing
embryo initiates a stratification program
culminating in the formation of the epidermal
barrier. (b) In wild-type mice, epidermal
stratification and barrier formation are
completed by birth. The surface ectoderm of
mice lacking the transcription factor p63 fails
to adopt an epidermal fate, and therefore
stratification and barrier formation do not
occur. As a consequence, mice lacking p63
are born with a single layer of ectodermal
cells covering their bodies and die shortly
after birth due to dehydration. (c) Images of 
p63−/− and wild-type mice. 
After this initial commitment step, keratinocytes in the newly established embryonic 
basal layer give rise to a second layer of cells, the periderm (M’Boneko and Merker; 
1988). The periderm is shed before birth in conjunction with the acquisition of 
epidermal barrier function (Hardman et al. 1998). The next layer of the epidermis to 
form is the intermediate cell layer, which develops between the basal layer and the 
periderm (Smart et al; 1970). Development of this layer is associated with 
asymmetric cell division of embryonic basal keratinocytes (Lechler and Fuchs; 2005, 
Smart et al; 1970).  
Like basal keratinocytes, intermediate cells undergo  proliferation, and the loss of this 
proliferative capacity is associated with the maturation of intermediate cells into 
spinous cells (Koster et al. 2007, Smart 1970). 
Spinous cells subsequently undergo further maturation into granular and cornified 
cells. The morphological changes that are a hallmark of epidermal stratification are 
associated with changes in the expression of keratin differentiation markers (Koster 
and Roop; 2004).  
 
 
 
 
 
 
 
 Primary p63−/− surface epithelial cells are blocked in their commitment to a stratified epithelial lineage. Differentiation 
markers K5 and K14, which are expressed in epithelia that have committed 
to a stratification program, are not expressed in primary p63−/− cells. These cells do, however, express K18, a marker 
for singlelayered epithelia 
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For example, whereas the uncommitted surface ectoderm expresses keratins K8 and 
K18 (Moll et al. 1982), K5 and K14 are induced as these cells commit to an 
epidermal fate (Byrne et al. 1994). Subsequently, the initiation of terminal 
differentiation results in the induction of K1 and K10 expression in the newly formed 
suprabasal keratinocytes (Bickenbach et al. 1995, Fuchs and  Green; 1980). 
The final step in epidermal stratification involves the formation of the epidermal 
barrier. During normal development, barrier acquisition is patterned and initiates at 
the dorsal surface, spreading laterally to the ventral surface in approximately one day 
(Hardman et al; 1998). The process of barrier formation is characterized by the 
formation of cornified cell envelopes, composed of proteins crosslinked into a rigid 
scaffold and of lipids covalently attached to the exterior surface (Rice and Green; 
1977, Steven and Steinert;  1994). Although established in utero, the barrier function 
of the epidermis is maintained during postnatal life owing to the continuous 
selfrenewal of the epidermis, a process mediated by epidermal stem cells (Blanpain 
and Fuchs; 2006). Under homeostatic conditions, the epidermal stem cells that are 
located in the interfollicular epidermis are responsible for the maintenance of this 
structure (Ito et al. 2005). 
These stem cells represent a small proportion of basal keratinocytes and, through 
asymmetric cell division, give rise to a daughter stem cell and a transit-amplifying 
cell, which ultimately undergoes terminal differentiation (Dunnwald et al. 2003, 
Potten andMorris; 1988, Schneider et al. 2003). 
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Attempts to establish unequivocally the role of p63 in epithelial development are 
complicated by the fact that this protein exists in multiple isoforms with different, 
often contradictory, biological activities. Koster and Roop reported that TAp63 was 
expressed earlier than ∆Np63 ( Koster et al; 2004 ) during epidermal development. 
Thus, TAp63, but not ∆Np63α, was proposed to be required for the initiation of 
epidermal stratification. TAp63 was reputed to be the molecular switch responsible 
for epithelial stratification while ∆Np63 was believed to counteract the TAp63 
isoform allowing keratinocytes terminal differentiation( Koster et al; 2006 ). 
Accordingly, studies on transgenic mice, demonstrate that upregulated TAp63α 
expression resulted in skin hyperplasia and a failure of keratinocytes to properly 
differentiate (Candi et al; 2006 ). 
These data are in contrast with  other works where  ∆Np63 was reported to be the 
only isoform expressed in epidermal development, until E13 embryonal stage ( 
Mikkola et al; 2007. Laurikkala et al; 2006 ), and that ∆Np63 is expressed in the 
basal undifferentiated layer of the skin, in particular in the stem cell compartment, 
and was rapidly degraded when keratinocytes are induced to differentiate ( Yang et 
al; 1998. Pellegrini et al; 2001. Rossi et al; 2006 ). 
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 The down-regulation of ∆Np63 in suprabasal keratinocytes was recently shown to be 
mediated, at least in part, by signalling through Notch, which induces terminal 
differentiation of keratinocytes ( Nguyen et al; 2006 ). In vitro studies suggested that, 
in basal keratinocytes, ∆Np63α induces proliferation and prevents premature entry 
into terminal differentiation ( King et al; 2003. King et al; 2006). Consistent with this 
hypothesis, many currently identified ∆Np63 target genes are involved in 
proliferation or in preventing differentiation ( Westfall et al; 2003. Nguyen et al; 
2006. Wu et al; 2005. Sbisa et al; 2006). In particular ∆Np63α was reported to repress 
the expression of p21 and 14-3-3σ, two genes induced during epidermal terminal 
differentiation, and the expression of genes required for cell cycle progression 
including cyclin B2 and cdc2 ( Testoni et al; 2006). 
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In addition to maintaining the proliferative state of a subset of basal keratinocytes 
∆Np63α may also maintain the expression of the basal keratins K5 and K14. 
(Westfall et al; 2003. Nguyen et al; 2006. Missero et al; 1995).  
Later one, data from different groups have demonstrated coexpression of  ∆Np63 and 
TAp63α isotypes during embryonic development and differentiation of 
developmentally mature keratinocytes. Karin Nylander, using antibodies directed 
against specific p63 proteins, detected TAp63 in normal stratified epidermis ( 
Nylander et al; 2002 ). Paul Khavari’s group, using a siRNA approach directed 
against p63 in regenerating human epidermis, demonstrated that ∆Np63 isoforms 
downregulation was responsible for the majority of the skin defects while TAp63 
isoforms appeared to be relevant for late differentiation ( Truong et al; 2006). Our 
group has recently demonstrated that TAp63 starts to be expressed, together with 
∆Np63, at stage 11.5 of mouse embryo development in the skin of anterior and 
posterior limbs. Remarkably, the Dlx3 homeobox gene, a gene specifically expressed 
in the granular layer of the epidermis,  was found regulated by p63 during ectoderm 
development. Further underlying, the role of TAp63 in the epidermal stratification 
program. 
Two recent studies ( Carroll et al; 2006. Ihrie et al; 2005 ) have revealed a role for 
p63 in the transcriptional regulation of adhesion programs affecting both cell-cell and 
cell matrix interaction suggesting that p63 may direct the development of stratified 
epithelia by orchestrating a series of different programs important for tissue integrity 
and function. The first epithelial cell-cell adhesion protein identified as a direct target 
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of p63 transcriptional control was Perp. Perp knockout mice exhibited postnatal 
lethality associated with the presence of epithelial blistering, particularly in the skin 
and oral cavity. Further investigation into the cause of the observed lethality and 
epithelial integrity defects in the Perp knockout mice demonstrated that Perp is highly 
expressed in stratified epithelia, where it is a constituent of desmosomes, and further, 
that marked structural defects were present in the desmosomes of Perp-/- mice. A 
connection between p63 and Perp was identified, as expression of Perp depends on 
p63 during the epidermal stratification program, and p63 can directly regulate Perp. 
All isoforms of p63 can transactivated Perp, and further, chromatin 
immunoprecipitation (ChIP) analyses demonstrated p63 occupancy of p53/p63 sites 
in the Perp gene in vivo, in the epidermis. These studies revealed that p63 controls 
aspects of cell-cell adhesion through induction of Perp expression. It has suggested 
that p63 can regulate the expression of an entire axis of cellular adhesion. Multiple 
genes, such as integrins 3,4, 5 and 6, laminin, two cadherins, plakoglobin and other 
can be, directly or indirectly, regulated by ∆Np63 or TA isoforms. Interestingly, 
ablation of both integrin α3 and α6 genes causes severe bilateral hypoplasia and limb 
malformation, resulting from a defect in the morphogenesis of the apical ectodermal 
ridge ( AER ) ( De Arcangelis et al; 1999). The defects in limb formation and the 
AER observed in the double knockout model bear some resemblance to those seen in 
the p63 null mice. Since p63 can directly regulate the expression of both of these 
integrins ( Carroll et al; 2006; Kurata et al; 2004 ), the failure to establish and 
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differentiate the AER in the p63 null mice could be at least partially caused by the 
reduction or loss of α3 and α6 integrin expression in these animals. 
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P63 human associated disorders  
 
Mutations in the p63 gene can cause at least five different syndromes: Ectrodactyly, 
Ectodermal dysplasia and Cleft lip/palate syndrome (EEC, OMIM 604292), 
Ankyloblepharon - Ectodermal defects - Cleft lip/palate syndrome (AEC, OMIM 
106260), Limb Mammary Syndrome (LMS, OMIM 603543), Acro-Dermato-Ungual-
Lacrimal-Tooth syndrome (ADULT, OMIM 103285) and Rapp-Hodgkin Syndrome 
(RHS, OMIM 129400). Furthermore, two non-syndromic human disorders are caused 
by p63 mutations: isolated Split Hand/Foot Malformation (SHFM4, OMIM 605289) 
and recently non-syndromic cleft lip ( Leoyklang et al; 2006). Human phenotypes 
caused by mutation in p63 gene resemble that of p63-knockout mice and are 
characterized by ectodermal dysplasia, split hand/foot malformation and orofacial 
clefting.  
 
 
Lack of epidermis
 
 
Lack of mammary 
and prostate glands 
 
  
 
Cleft lips and palate,
lack of teeths, facial 
dysmorphism 
Truncated limbs 
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and hair Mammari gland 
hipoplasiaCleft lip and 
palate, ipodontia
  
 
 
 
 
 
 
 Distribution of mutation in p63, revealing a striking genotype-phenotype correlation. The 
approximate positions of truncating mutations and aminoacid correlation are indicated. 
 
 The localization and functional effects of the mutations that underlie these 
syndromes establish a striking genotype-phenotype correlation.  
The prototype of the p63 syndrome family is the EEC syndrome characterized by 
ectrodactyly dysplasia, ectodermal dysplasia and facial clefts. Ectodermal dysplasia 
affects the skin and other ectodermal derivates such as teeth, hair and nails. Clefting 
affects the lip, sometimes in combination with palate. Other symptoms are lacrimal-
duct abnormalities, urogenitals problems and facial dysmorphism. EEC syndrome is 
mainly caused by point mutations in the DNA binding domain (DBD) of the p63 
gene. Altogether 34 different mutations have been reported, and 20 different amino 
acids are involved. Only two mutations are outside the DNA binding domain: one 
insertion (1572 InsA) and one point mutation (L563P) in the Sterile Alpha Motif 
domain (SAM). Five frequently mutated amino acids were found in the EEC 
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population: R204, R227, R279, R280 and R304, all located in CpG islands. The five 
p63 arginine hotspot mutations and probably also other DNA binding domain 
mutations that are found in EEC syndrome appear to affect the DNA binding capacity 
of p63, which results in impaired transactivation activity and altered regulation of 
transactivation. The autosomal dominant inheritance of EEC syndrome suggests that 
the EEC mutations have a dominant negative effect. However, recent genotype-
phenotype analyses for the five hotspot mutations revealed significant differences 
between the corresponding phenotypes. For instance cleft lip/palate is present in the 
R304 mutation population (80%), whereas R227 patients seldom have cleft lip/palate. 
Syndactyly is completely absent in R227 population, while 30-60% of the other 
hotspot mutation population have syndactyly. It thus seems that these hotspot 
mutations exert specific effects. Such specificity might be brought about by different 
effects of these mutations on promoters for p63 transcriptional target genes. 
Alternatively, these hotspot mutations may exhibit gain-of-function effects, similar as 
for the p53 hotspot mutations.  
AEC syndrome, which is also known as “ Hay-Wells syndrome” has little or no limb 
involvement but instead includes ankyloblepharon, which is a partial or complete 
fusion of the eyelids that is very rare in other EEC- like syndrome. In addition to 
these major features, eroded skin at birth and recurrent scalp infection are important 
sign. The other Ectodermal Dysplasia symptoms, such as nail and teeth defects are 
present in more than 80% of patients, and hair defects and/or alopecia are almost 
constant features. AEC syndrome is caused by missense mutation within the SAM 
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domain of p63 ( McGrath et al; 2001). These mutation are predicted to disrupt 
protein-protein interaction, by either destroying the compact globular structure of the 
SAM domain or substituting amino acids that are crucial for such interaction ( 
McGrath et al; 2001).  
Rapp-Hodgkin syndrome (RHS) mimics AEC very much. Such AEC, even RHS is 
caused by mutation in SAM domain, and for this reason affecting only the α isoforms 
(Kantaputra et al; 2003). RHS has characterized by ankyloblepharon and the more 
severe skin phenotype in AEC ( Rinne et al; 2006 Bertola et al; 2004). Other ED 
symptoms, such as orofacial clefting and the near absence of limb malformations are 
similar to AEC. Although, the severity of the skin phenotype is obvious and much 
more severe in AEC patients than in RHS patients, the strong overlap between AEC 
and RHS suggest, that they are variable manifestations of the same clinical entity. 
LMS syndrome is caused by mutations located in the N- and C-terminus of the p63 
gene. A large LMS family (29 affected members) has a point mutation in the exon 4 
(G76W) in the putative second transactivation domain (TA2) ( vanBokhoven et al; 
2002;  Duijf et al; 2002). One other point mutation (S90W) is also located between 
the TA domain and DBD. Other LMS mutations are reported in the C-terminus: a TT 
deletion in the exon 13 and a AA deletion in exon 14. These will affect only the p63α 
protein isoforms, where they are predicted to cause a frame shift and a premature stop 
codon. Also a stop mutation in the transcription factor inhibitory domain (TI) 
(K632X) has been identified in a sporadic LMS patient.11  
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The LMS phenotype resembles the EEC syndrome phenotype, but the ectodermal 
manifestations are milder ( vanBokhoven et al; 1999) A consistent feature of LMS is 
the mammary gland and/or nipple hypoplasia, moreover lacrimal duct obstruction and 
dystrophic nails are frequently observed. Hypohydrosis and teeth defects are 
detected, but other ectodermal defects such as hair and skin defects are rarely 
detected if at all. About 70% of LMS patients have similar limb malformations as in 
EEC syndrome, and about 30% orofacial clefting, notably always in form of cleft 
palate ( Rinne et al; 2006). 
 ADULT syndrome phenotype is most similar to LMS syndrome, although clear 
differences can be seen when observing larger families or patient populations. The 
main difference is the absence of orofacial clefting and the presence of hair and skin 
defects in the ADULT syndrome. Teeth, skin and nail defects are constantly present 
in ADULT syndrome, but only rarely in LMS. Hair (53%) and lacrimal duct defects 
(67%) are observed in ADULT patients more frequently than in LMS.  
ADULT syndrome is characterized by point mutation in exon 8, changing R298 in 
the DNA binding domain into either a glutamine or a glycine. While EEC syndrome 
mutations in the DNA binding domain impair the binding of p63 protein to DNA, 
arginine 298 is not located close to the DNA-binding interface, and mutation of this 
arginine does not affect DNA binding. Instead, earlier studies have shown a gain-of-
function effect for the mutated ∆Np63γ isoform, which usually does not have a 
transactivation activity in assays using an optimized p53-responsive element ( Duijf 
et al; 2002. Rinne et al; 2006).Two other mutations are located in the N-terminus: 
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N6H mutation affects only the ∆N-isoforms and in another isolated patient a 
missense mutation G134D is located just front of the DBD in exon 4 ( Slavotinek et 
al; 2005).  
Split Hand/Foot Malformation type 4 (SHFM4) is a “pure” limb malformation 
(ectrodactyly and syndactyly) condition, thus without orofacial clefting or ectodermal 
dysplasia. The non-syndromic SHFM4 is caused by several mutations, which are 
dispersed throughout the p63 gene: a point mutation in the Transactivation domain 
(TA) (R58C), a splice-site mutation in front of exon 4, four missense mutations in the 
DNA binding domain (K193E, K194E, R280C, R280H), and two nonsense mutations 
in the TI-domain (Q634X, E639X). It is still unclear how these widely dispersed 
mutations cause the limb defect. Interestingly, several SHFM4 mutations are reported 
to cause alteration in the p63 protein activation and stability: Q634X and E639X are 
known to disrupt the sumoylation site, and therefore increase the stability and 
transcriptional activity of the p63alpha isoform (Huang et al; 2004. Ghioni et al; 
2005). Furthermore, amino acids K193 and K194 are required for ubiquitin 
conjugation by E3 ubiquitin ligase (Itch) and naturally occurring mutations in those 
amino acids cause more stable p63 protein ( Rossi M et al; 2006). Possibly, SHFM is 
caused by altered protein degradation, even though different degradation routes are 
involved.  
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P63 protein regulation 
 
Very little is known of the molecular mechanisms underlying the regulation of p63 
protein steady-state levels. In response to different extrinsic and intrinsic cell signals, 
sophisticated molecular mechanisms must operate in order to activate one or the other 
p53 family member and to switch on the particular isoform whose specific activity is 
required. These mechanisms are expected to finely operate keeping a right balance 
among these proteins either in a physiological or stress condition. 
 Following oncogenic and stress signals, p53 is stabilized and biochemically 
activated, leading to transcriptional upregulation or repression of a multitude of target 
genes. The principal regulator of p53 protein levels is assumed to be the E3 ubiquitin 
ligase MDM2. MDM2 binds to and ubiquitinates p53, driving it to degradation by the 
26S proteasome. In addition to MDM2, other E3 ligases, such as Pirh2 and COP1, 
have been shown to regulate p53 levels. The p14ARF tumor suppressor protein 
antagonizes MDM2 activity leading to p53 stabilization. 
Data from our lab and others show that p63 protein level is mainly regulated by 
Itch/AIP4, a HECT E3-ubiquitin ligase that drives p63 to lysosome-mediated 
degradation (Rossi et al; Cell Cycle 2006; Rossi et al; PNAs 2006). Furthermore, 
sumoylation of ∆Np63α affects protein stability and transcriptional activity (Ghioni 
et al; 2005). Recent data have indicated that PML protein interacts with p63 
increasing its protein level as well as its transcriptional ability ( Bernassola et al; 
2005), such as SSRP1 and p300 that function as p63 co-activators ( Zeng et al; 2002; 
MacPartlin et al; 2005).  
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Moreover, work in our lab has demonstrated that MDM2 and p14ARF, two 
components of the principal p53 regulatory pathway, are also involved in the control 
of p63 stability and activity, although their effects on p63 appear to be quite different 
(Calabrò et al; 2002; Calabrò et al; 2004). In particular, it has been shown that 
p14ARF physically associates with p63 (Calabrò et al; 2004) and, unexpectedly, it 
has a negative function on p63 activity, suggesting that p14ARF might not only 
stabilize p53 but also sequester and store p63, in an inactive complex.  Thus, the 
molecular mechanisms regulating p53, and p63 appear to have largely diverged even 
though they share some components.  
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 Unequivocal establishment of the role of p63 in the pathogenesis of human 
ectodermal syndromes is complicated by the fact that this protein exists in multiple 
isoforms with different often contradictory biological activities. The roles of TA and 
∆N isoforms in stratified epithelia have still remained enigmatic. Their spatial and 
temporal expression pattern suggests that the regulation of p63 function must be 
much more complex than that believed so far and that sophisticated molecular 
mechanisms must operate in order to switch on the particular isoform whose specific 
activity is required in a particular context and in the response to specific extrinsic and 
intrinsic cell signal. 
 The profile of identified p63 proteins partners, that may modulate its transcriptional 
activity, as well as its transcriptional target genes,  is currently limited. 
My research activity, during the last three years, has been focused on the clarification 
of  the molecular mechanisms  through which p63 exerts its function  using two 
different but complementary approaches, i.e. the identification of p63 specific 
transcriptional targets and the study of the mechanisms regulating p63 protein 
transcriptional activity and stability.  
1)As several developmental disorders associated to ectodermal dysplasia are caused 
by p63 mutation in humans  I decided first to identify p63 specific transcriptional 
targets that were relevant for the pathogenesis of human AEC syndromes.  
All the naturally occurring AEC mutations occur  in the p63 SAM-domain and model 
structure has been used to divide  AEC mutations in two groups. The first (L518V, 
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I541T, C526W) includes mutations in amino acids that are predicted to be buried 
inside the protein and are believed to affect its overall structure and stability. The 
second (G534V, T537P and Q540L), whose direct effect on the protein is less 
obvious, contains all the other amino acids that have a larger solvent accessible 
surface and are not predicted to cause gross conformational changes ( Brunner et al; 
2002). These AEC mutations may disrupt the structural integrity of the SAM domain 
or interfere with particular protein-protein interactions. They have, in fact, already 
been shown to disrupt the interaction of p63 with the Apobec-1 binding protein-
1(ABPP1) and thus alter the splicing mechanism of fibroblast growth factor receptor-
2, FGFR2( Fomenkov et al; 2003). 
To gain information about the effects of the Q540L mutation on p63 functions I 
generated stable cell lines that express wild type TAp63α, ∆Np63α or the 
TAp63αQ540L mutant under the control of a TET inducible promoter. I used this 
experimental system to systematically compare the effects of the mutant and wild 
type p63 proteins on cell proliferation and to generate, by microarrays analysis, a 
comprehensive profile of differential gene expression. I found that the Q540L 
substitution affects the transcriptional activity of TAp63α and it causes misregulation 
of genes involved in the control of cell growth and epidermal differentiation. 
2) Interestingly, our group has also demonstrated that AEC-derived TAp63 proteins 
exhibit an impaired ability to transactivate Dlx3, thus suggesting that the 
misregulation of the Dlx3 gene is involved in the pathogenesis of AEC.  
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Dlx3 is a transcription factor belonging to the Distal-less family of homeodomain 
proteins. It plays a central roles in embryonic pattern and regulation of different 
developmental processes. The Distal-less family of proteins are all related to 
Drosophila Distalless homeodomain gene. 
Dlx3, in mouse, is expressed in terminally differentiated epidermal cells, and there is 
evidence to support an essential role as a transcriptional regulator of the terminal 
differentiation process. Dlx3 is activated in primary mouse keratinocytes cultured in 
vitro by increasing the level of extracellular Ca2+.  
Like p63, mutations in the DLX3 gene have been directly linked with human 
ectodermal dysplasias. Dlx3 molecular alteration causes tricho-dento osseous 
syndrome (TDO) and amelogenesis imperfecta hypoplastic-hypomaturation with 
taurodontism (AIHHT). TDO is characterized by defects in the development of hair 
and teeth, increased bone density in the cranium, and absence of overt limb 
malformations (Wright et al., 1997;Price et al., 1998). The mutation is due to a 4-bp 
deletion immediately downstream of the homeobox region (DNA binding domain), 
resulting in a truncated DLX3 protein C-terminus that can potentially still bind DNA 
but is functionally altered. In humans, the TDO mutation results in a dominant 
phenotype. It is interesting to note that p63 and Dlx3 mutations resulted in partial-
overlapping phenotypes characterized by defects in the same structure, such as hair, 
teeth and bone, and by absence of limb malformation ( Price et al; 1998). suggesting 
that these genes belong to a common signaling cascades regulating epidermal 
development.  
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In the attempt to clarify the relationship between Dlx3 and p63, I performed  transient 
expression assays of Dlx3 in immortalized human HaCaT keratinocytes. The results 
clearly have shown a reduction of endogenous ∆Np63α protein. Such reduction was 
also observed on exogenously expressed p63 protein thus suggesting that p63 
downregulation occurs at protein level. I have thus focused on the elucidation of the 
pathway and players through which Dlx3 regulates the p63 protein turnover. 
3) Finally, as in our lab has been demonstrated that p63 directly interacts with 
p14ARF and that throught this interaction ARF inhibits p63-mediated transactivation 
and transrepression I decided to try to elucidate the mechanism through which 
p14ARF is able to inhibit p63 transcriptional activity. 
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 1) DIFFERENTIAL GENE EXPRESSION ANALYSIS TO IDENTIFY P63 
SPECIFIC TRANSCRIPTIONAL TARGETS  
   
1.1) Production and characterization of TAp63α, TAp63αQ540L and ∆Np63α 
stable cell lines. 
To investigate on the effects of the Q540L mutation on p63 protein functions I 
generated stable H1299 cell lines, expressing TAp63α, ∆Np63α or 
TAp63αQ540L, under a tetracycline/doxycycline (dox)-inducible promoter using 
Tet-On Gene Expression System (see materials and methods). The Tet-On system 
has several advantages over other regulated gene expression systems that function 
in mammalian cells. In fact, Tet-On  system assures no pleiotropic effects, 
extremely tight on/off regulation, high inducibility and fast response times.  
I first analysed, by Western blot, the timing and level of expression of TAp63αwt, 
TAp63αQ540L and ∆Np63α proteins in stable clones upon dox induction. Results 
from representative cell lines for TAp63αwt, TAp63αQ540L and ∆Np63α are 
shown in Figure 1. Without dox in the medium p63 proteins were undetectable. 
Following addition of 1 µg/ml doxycycline in the culture medium, p63 proteins 
were induced in a time-dependent manner (fig. 1). At 24 hrs of induction, p63 
proteins were already abundant and their expression levels were comparable . 
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Figure 1. Expression of p63 isoforms in H1299 stable clones.  
Western Blot analysis for detection of the p63 protein expression levels in Dox-inducible H1299 cells. Cells were
harvested  and p63 expression level was analized at the indicated time points and  with different amounts ( 0.5, 1
and 2µg ) of inductor. Equal amounts of soluble lysates ( 30µg)  from uninduced and induced clones expressing
wild-type TAp63α, ∆Np63α or the mutant TAp63Q540Lprotein were evaluated for p63 protein levels by western
blotting using an anti-p63 antibody ( 4A4, Santa Cruz). A) The timing of expression was assessed at 48 hours
after inductor, while B) expression upon addition  of different amounts of doxicycline into the medium was
assessed at 1µg.  
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The high degree of similarity between p53, and p63 DNA-binding domains, as well 
as transactivation and oligomerization domains, suggested that p63 could regulate 
p53 target genes. Actually, It has been reported that some p63 isoforms such as 
TAp63, are able to regulate the transcription of p53 target genes such as p21WAF 
and MDM2 ( Yang et al; 2000). In order to verify the transcriptional activity of 
∆Np63α as well as the effect of Q540L point mutation on the activity of TAp63α I 
tested the effect of TAp63α, ∆Np63α and the Q540L mutant expression on p21WAF 
and MDM2 endogenous gene expression. Stable cell lines expressing, respectively, 
TAp63α, ∆Np63α and TAp63Q540L were induced for 48 hours with different 
amounts of doxycycline. The results of Western Blot analysis showed an increase of 
p21WAF and MDM2 protein expression levels upon TAp63α and ∆Np63α induction, 
though to a different extent. In contrast, AEC mutant Q540L appeared to reduce p21 
and MDM2 expression ( Figure 2A). I have also analyzed the effect of Q540L point 
substitution on the ability of TAp63α wt protein to transactivate the expression of a 
CAT reporter gene under the control of the p21WAF gene promoter. A fixed amount 
of p21/WAF promoter-CAT construct was transiently transfected in H1299 cell lines 
along with increasing amounts of plasmids encoding p63α proteins. As shown in 
Figure 2B, the Q540L mutation strongly impairs the ability of TAp63α to induce the 
p21/WAF gene promoter, whereas ∆Np63α is a mild activator. 
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Figure 2. TAp63αQ540L has lost the ability to activate p21/WAF and MDM2 gene expression.  
A) Western Blot analysis showing expression of TAp63α wt, TAp63αQ540L and ∆Np63α proteins in stable clones at 48h 
upon induction with the indicated amounts of doxycycline. The expression of endogenous MDM2 and p21/WAF proteins 
was also evaluated by specific immunodetection. MDM2 and p21/WAF protein levels increase in parallel with TAp63α and
∆Np63α induction, but decrease upon TAp63αQ540L induction. β-Actin was used as a protein loading control. 
B)H1299 were transiently transfected with 2µg of p21/WAF-CAT reporter plasmid/dish alone or with different amounts of
each p63expressing plasmid ( 1, 2 or 3 µg). After 48h, cells were harvested, and CAT acivity was determined. The basal 
activity of the reporter was set at 1. The data are presented as fold induction relative to the sample without effector ( white
bar). Each histogram bar represent the mean of triplicate assays from three independent experiments. Standard deviation are
also indicated.  
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1.2) Subcellular localization of mutant TAp63αQ540L 
 
 
 TAp63α and ∆Np63α proteins are located in the nucleus where they act as 
transcriptional factors ( Calabrò et al; 2004). 
For this reason, we have supposed that the lack of transcriptional activity of the 
TAp63αQ540L protein could to be due to its inability to relocate in the nucleus. 
So, I performed subcellular immunolocalization assay on induced or uninduced stable 
clones expressing TAp63α , ∆Np63α and mutant Q540L protein to compare TA,  
∆Np63α wild type and TAp63αQ540L subcellular distribution in Tet-On stable 
H1299 cells. Fourty-eihgt hours after induction, cells were fixed and immunorevealed 
with antibody to detect p63 protein. Inspection of the subcellular localization of 
TAp63α, ∆Np63α and TAp63αQ540L protein expressed in our inducible clones, by 
immunofluorescence, showed that, both p63α wild type and mutant Q540L proteins 
were uniformly distributed in the nucleus with nucleolar sparing ( Figure 3). 
Therefore, the Q540L amino acid substitution does not alter TAp63α subcellular 
distribution. 
 
 
 
 
 
 
 41
DAPI ∆Np63α I TAp63α 
 
 
 
 
 
 
 
 
DAPI TAp63Q540L  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3. The Q540L AEC-mutant  localize into the nucleus.  Subcellular localization assay are 
performed in TAp63α , ∆Np63α and TAp63αQ540L stable cell line under induced ( +dox) condition. 
The cells were examined under a fluorescence microscope. As shown, both p63α wild type and Q540L 
mutant protein localize into the nucleus. 42DAP
 1.3) Functional analysis of stable clones expressing TAp63α, ∆Np63α and 
TAp63αQ540L 
 
To test the effects of wild type TAp63α, ∆Np63α and mutant TAp63αQ540L 
protein on cell proliferation, I compared the cell growth profile of H1299 cells, 
expressing wild type TAp63α, ∆Np63α, or  TAp63αQ540L. Interestingly, cells 
expressing wild type TA or ∆Np63α showed a reduction of cell growth rate while 
the cell growth profile was completely unaffected by TAp63αQ540L expression 
(fig. 4A, B and C). By the trypan blue dye exclusion assay, I could estimate that 
at 72 hrs after induction, TAp63α expression induced a 9.2% of cell death while 
∆Np63α a 3.4 %. Again TAp63αQ540L had completely no effect on cell viability 
(fig. 4D). Then, I performed flow cytometric analysis on p63 inducible clones. In 
a dox free culture medium, the cell cycle profile of the three p63 stable cell lines 
and parental H1299 cell line were comparable (fig. 4E and data not shown). 
However, at 48 hrs upon addition of 1 µg/ml of dox, both wild type TA and 
∆Np63α caused a G1 cell cycle arrest, with a parallel reduction in S and G2/M 
phases and a significant increase of sub-G1 events (fig.4E). In contrast, when the 
TAp63αQ540L mutant was induced, the percentage of cells in G1 phase was 
unaffected and a slight increase in S phase with a corresponding decrease in G2-
M phase was observed (fig. 4E).  
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Figure 4. The Q540L aminoacid substitution impairs the ability of wild type TAp63α to induce a G1 cell 
cycle arrest and cell death.   
Cell growth profiles of TAp63α (A), ∆Np63α (B) and TAp63αQ540L (C) stable cell lines under induced (+ 
dox) or uninduced (-dox) conditions. The growth rate was measured as described in Materials and methods. 
(D) TAp63α, ∆Np63α and TAp63αQ540L stable clones, induced (+dox) or uninduced (-dox) to express the 
respective p63 proteins for 3 days, were analysed for the percentage of dead cells (blue cells/total cells) by 
trypan blue dye staining as described in Materials and methods. (E) DNA content distribution of TAp63α, 
∆Np63α and TAp63αQ540L cells, expressing (+dox) or not (-dox) the respective p63 proteins, analysed for 
DNA content by propidium iodide staining of fixed cells. Standard deviations are also indicated. 
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1.4) Microarray analysis  
 
The finding that TAp63α inhibits cell proliferation and induces cell death, 
whereas the TAp63αQ540L mutant lacks these capabilities prompted us to  
generate a comprehensive profile of differential gene expression by Microarray 
analysis. I extracted and purified total RNA from stable H1299 cell lines ( see 
Matherial and Methods). Microarray analysis was performed in the lab of Prof. 
Calogero in Turin. Four prototypic situation were evaluated: a) TAp63α wt 
without induction, b) TAp63α wt with induction, c) TAp63αQ540L without 
induction, d) TAp63αQ540L with induction. Three biological replicas generated 
for all four situation were used to synthesize biotinylated cRNA for hybridization 
on arrays containing 54675 probes. Microarray data have shown that there is a 
clear up-modulation of the wild type and mutant p63 proteins upon induction with 
doxycycline (fig. 5). Up-modulation of p63 was also confirmed by real-time PCR 
(data not shown). A total of 45 probe set ids were identified as differentially 
expressed and associated to 36 gene IDs. Quantitative RT real-time PCR (QPCR) 
validation was done for 11 out of 36 genes. A total of 10 annotated genes, that 
were transactivated upon induction of wild type TAp63α (fig. 5D), resulted not to 
be responsive to the TAp63αQ540L mutant. Among this set of genes, 4 of them 
(GDF15, CDKNIA/p21WAF, MDM2, ARX) were selected to be also 
investigated by QPCR for their responsiveness to TAp63α, ∆Np63α and 
TAp63αQ540L (fig. 6). GDF15 and CDKNIA-p21WAF appeared to be 
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significantly transactivated by TAp63α only. GDF15 was already activated at 12 
hrs of induction (fig. 6A) while p21WAF after 24 hrs (fig 6B). MDM2 and ARX 
were similarly transactivated by wild type TA and ∆Np63α (fig. 6C and D) but 
none of these four genes were  modulated by the TAp63αQ540L mutant (fig 6A 
and D). According to data that I obtained from both CAT reporter assay and 
western blot analysis, also Microarray data have showed no increase of p21/WAF 
and MDM2 endogenous proteins in TAp63αQ540L stable cells upon induction. 
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Probe QPCR Symbol GeneID Chr Loc. 
Wt 229399_at --- C10orf118 55088 10q25.3 
242134_at --- --- --- --- 
237105_at --- --- --- 2q31.2 
1557257_at --- BCL10 8915 1p22 
210310_s_at T FGF5 2250 4q21 
211022_s_at --- ATRX 546 Xq13.1-q21.1 
214390_s_at --- BCAT1 586 12pter-q12 
1561939_at --- DNCH2 79659 11q21-q22.1 
241955_at --- HECTD1 25831 14q12 
231791_at --- ASAH2 56624 --- 
222891_s_at --- BCL11A 53335 2p16.1 
206112_at --- ANKRD7 56311 7q31 
236356_at --- NDUFS1 4719 2q33-q34 
1555153_s_at --- FCHO2 115548 5q13.2 
215092_s_at --- NFAT5 10725 16q22.1 
241765_at T CPM 1368 12q14.3 
204622_x_at --- NR4A2 4929 2q22-q23 
233320_at --- TCAM1 146771 17q22 
235009_at --- FAM44A 259282 4p16.1 
224568_x_at --- MALAT1 378938 11cen-q12.3 
1552368_at T CTCFL 140690 20q13.31 
227510_x_at --- --- --- 11cen-q12.3 
224917_at --- VMP1 81671 17q23.2 
-3 A
1
3
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Probe            QPCR      Symbol       GeneID       Chr 206463_s_at --- DHRS2 10202 14q11.2         
214079_at --- DHRS2 10202 14q11.2 B
221042_s_at      ---        CLMN             79789        
14q32.13 
207714_s_at      ---        SERPINH1     871            11q13.5
1557948_at        ---        PHLDB3         284345      
19q13.31 
1554140_at        ---           ---                  ---            1p31.2 
1552519_at        ---        ACVR1C        130399      2q24.1 
223044_at          ---        SLC40A1       30061        2q32 
C
221577_x_at Y GDF15 9518 19p13.1-13.2 
238878_at Y ARX 170302 Xp22.1-p21.3 
205386_s_at Y MDM2 4193 12q14.3-q15 
217373_x_at Y MDM2 4193 12q14.3-q15 
236937_at --- KIAA0804 23355 3q27.2 
202284_s_at Y CDKN1A (p21) 1026 6p21.2 
242183_at --- --- 126298 19q13.31 
1559322_at N PTP4A1 7803 6q12 
231307_at --- ---  ---  Xp11.22 
209732_at --- CLECSF2 9976 12p13-p12 
204286_s_at Y PMAIP1 5366 18q21.32 
223853_at Y BVES 11149 6q21 
207813_s_at Y FDXR 2232 17q24-q25 
238733_at  ---  ---  ---  --- 
D
211834_s_at Y      TP73L        8626       3q27-q29  
           (p63) 
 
 
Figure 5. Clustering of probe sets differentially expressed between TAp63α wt and Q540L mutant 
stable cell lines. Cluster A refers to genes which are not significantly modulated upon induction of 
TAp63α wild type and are instead down-modulated by TAp63αQ540L expression. Cluster B includes 
only one gene which is down-modulated by TAp63α wild type expression and not significantly 
modulated by TAp63αQ540L. Cluster C encloses genes which are not significantly modulated upon 
induction of TAp63α wild type and are instead up-modulated by the TAp63αQ540L mutant protein. 
Cluster D refers to genes transactivated by the wild type TAp63α protein and characterized by a loss of 
regulation by the TAp63αQ540L mutant.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. QPCR data related to 4 genes transactivated by TAp63α wild type and 
characterized by a loss of control by the Q540L mutant.  Gene expression was analyzed at 
12 and 24 hours upon addition of doxycycline to ∆Np63α, TAp63α and Q540LTAp63α 
inducible cell lines. Target gene mRNA levels were normalized for ACTB (white bars) and 
POL2 (black bars) and expressed as –DDCt (i.e. not-induced cell line-induced cell line Cts).  
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1.5) TAp63αQ540L binds to p21 promoter sequences in vitro and interacts with 
Sp1 in vivo. 
 
 The absolute inability of the TAp63αQ540L protein to transactivate the p21WAF 
promoter prompted us to verify whether the mutant protein was still capable to 
bind to the p53-consensus sequence of the p21WAF promoter.  Thus I compared 
the DNA binding capacity of wild type and mutant TAp63α proteins by an in 
vitro DNA-binding assay. A radiolabeled duplex oligonucleotide representing a 
p53-binding site previously identified in the p21/WAF promoter, was used as 
target DNA (Calabrò, Mansueto et al. 2004). Incubation of the radiolabeled 
oligonucleotide with in vitro translated TAp63α or TAp63αQ540L mutant, led to 
the formation of specific protein-DNA complexes (Fig.7 A, lanes 2 and 6). The 
specificity of the TAp63-DNA complexes was tested by a competition 
experiment: a 100x cold molar excess of the same oligonucleotide used as probe 
completely abolished the binding, while an unrelevant control oligonucleotide 
had no effect (Figure 7, lanes 3 and 4; 7 and 8). The identity of the TAp63α-DNA 
complexes was confirmed by a supershift experiment (Figure 7, panel A, lanes 5 
and 9) by incubating the in vitro translated TAp63α proteins prior to the binding 
reaction, with an antibody recognizing the p63 DNA-binding domain. By 
Western blot analysis we verified that the relative abundance of the in vitro 
translated TAp63 proteins was comparable (data not shown). These observations 
indicate that the wild type TAp63α protein specifically binds to a p53 consensus 
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sequence of the p21/WAF promoter and that the Q540L mutation does not affect 
this binding, at least in this in vitro assay. 
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 Figure 7. TAp63αQ540L binds to p53 consensus site in the p21/WAF target promoter and it is 
able to associate with the Sp1 transcription factor.  
(A) The indicated p63 proteins were in vitro translated by using TnT reticulocytes from Promega and 
0.5 µg of each p63 plasmid DNA. Equal amounts of the individual reactions were subjected to EMSA 
using a 32P-labelled oligo containing a p53-binding site present in the p21 promoter (p21.1 probe). Cold 
competition was performed using either the 100-fold molar excess of the same oligonucleotide (lanes 3 
and 7) or an oligonucleotide containing a consensus binding site for E2F1 (lanes 4 and 8). For the 
supershift anti-p63 antibodies (4A4; SantaCruz) were used, adding them to the sample prior to the 
binding reaction (lanes 5 and 10). 50
The promoter of the human p21/WAF gene is characterized by a set of six Sp1 
binding sites located in the proximal region (nucleotides –120 to –40) and two 
distal p53 binding sites. These proximal Sp1 binding sites were shown to be 
essential for the activation of p21/WAF promoter by p53 ( Koutsodontis et al; 
2005). Since it has previously been reported that the γ isoform of TAp63 directly 
interacts with Sp1, we decided to investigate on whether TAp63α was also able to 
interact with Sp1 and, in this case, which was the effect of the Q540L substitution 
on this interaction. I performed co-immunoprecipitation experiments in TAp63α 
and TAp63αQ540L expressing cell lines induced or not with doxycycline. As 
shown in fig. 8, both wild type and mutant TAp63α proteins were 
immunoprecipitated using a Sp1 polyclonal antibody. The reciprocal 
immunoprecipitation, detecting Sp1 protein using the p63 monoclonal antibody 
did result in Sp1 being immunoprecipitated (data not shown). 
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 Figure 8. TAp63αQ540L associates with Sp1 transcription factor. 
Coimmunoprecipitation in TAp63α and TAp63αQ540L expressing cell lines. Both wt and mutant
TAp63α proteins were immunoprecipitated by a Sp1 polyclonal antibody only upon their induction
with doxycycline. 52
1.6) TAp63αQ540L does not bind  to p21 promoter sequences in vivo 
 
In vitro DNA-binding assay suggested  that the Q540L mutation does not affect the 
ability of the p63 protein to bind DNA. However, given the important role of 
chromatin structure in the regulation of gene expression by transcription factors and 
cofactors I would verify if the Q540L mutant protein was still able to bind p53-
consensus sites of the p21/WAF promoter, also an in vivo context. Thus, I performed 
Chromatin Immunoprecipitation Assay in H1299 cells transfected with TAp63α wild 
type or mutant Q540L encoding plasmids. Cross-linked chromatin was extracted and 
immunoprecipitated with anti-p63 antibody. DNA was purified and appropriately 
primers designed to amplify the p53-response element in p21/WAF, Dlx3, Jagged 2 
and IKK  promoters. In contrast with the previous reported data, obtained with an in 
vitro assay, in vivo cromatin Ip revealed that the AEC mutation impairs the ability of 
p63 to bind DNA. As shown in figure 9, wild type TAp63α protein specifically binds 
to promoter region of assayed genes, while the Q540L mutant shown significantly 
reduced ability to bind DNA. A Western Blot analysis of the transfected proteins 
have showed no significant differences in the relative abundance of p63α wild type 
and mutant protein ( data not shown).  
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 Figure 9. The Q540L substitution impairs DNA binding ability of p63. H1299 cells
were transfected with TAp63α wild type or mutant Q540L encoding plasmids.
Formaldeyde cross-linked chromatin was immunoprecipitated with anti-p63 4A4 antibody.
Eluted DNA was PCR amplified with primers specific for different p63 ( JAG 2, DLX 3)
and p53 ( p21WAF, IKK ) target promoters genes.   
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2) INVESTIGATION ON P63 PROTEIN DEGRADATION Dlx3-MEDIATED. 
  
2.1) Dlx3 downregulates  p63 protein level.  
Our group has also demonstrated that AEC-derived TAp63 proteins exhibit an 
impaired ability to transactivate Dlx3, thus suggesting that the misregulation of the 
Dlx3 gene is involved in the pathogenesis of AEC. It is interesting to note that p63 
and Dlx3 mutations resulted in partial-overlapping phenotypes characterized by 
defects in the same structure, such as hair, teeth and bone, and by absence of limb 
malformation ( Price et al; 1998) suggesting that these genes belong to a common 
signaling cascades regulating epidermal development.  
A recent work published by our group in collaboration with Dr. Morasso, has 
previously reported that calcium-induced differentiation of primary keratinocytes 
resulted in induction of Dlx3 gene expression that parallels a decrease of ∆Np63α 
specific transcripts (Radoja N. et al. 2007). Furthermore, transient expression of Dlx3 
induced a remarkable decrease of endogenous ∆Np63α protein expression both in 
primary Human Embryonic keratinocytes (HEK) ( data obtained in lab of Dr.  
Morasso from NIH of Bethesda) and immortalized HaCaT keratinocytes (Fig.10, 
panels A and B). As we suspected that Dlx3 was down-regulating ∆Np63α at the 
protein level, I transfected ∆Np63α or TAp63α expression vector alone, or in 
combination with increasing amount of Dlx3, in Saos2 cells, a human osteosarcoma-
derived cell line where p63 is not normally expressed. I transfected Saos2 cells with 
the indicated amount of expression vector by LipofectAMINE 2000 reagent and, after 
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24 hours, cells were lysated and protein concentrations determined using the Bio-Rad 
protein assay. Western blot of whole extracts and specific immunodetection with 
anti-p63 (4A4) antibodies and anti-Flag antibodies showed that Dlx3 caused a 
remarkable decrease of ∆Np63α  protein (Fig. 10 C). This effect was at protein level, 
since no difference in ∆Np63α specific transcript was detected when I performed 
semiquantitative RT-PCR on total RNA from Saos2 cells transfected with ∆Np63α 
alone or with Dlx3 (Fig.10 C). Compared to ∆Np63α, the abundance of TAp63α 
protein was less affected by Dlx3 expression (Fig.10 C).  I obtained similar results in 
different cellular context such as U2OS, HeLa, and H1299 cells. It has been 
previously demonstrated that p53 itself was able to associate with ∆Np63α inducing 
its degradation by a caspase-dependent mechanism ( Ratoviski et al; 2001), so, in 
order to investigate on whether Dlx3-mediated p63 degradation was involving p53 
activity, I performed experiments in (p53-/-mdm2-/-) Mouse Embryo Fibroblasts, 
MEFs (Fig.10 D). Thus I transfected MEFs with p63 alone or along with increasing 
amount of Dlx3 expression vector. Even in MEFs, I observed a decrease of p63 
protein, in response to Dlx3, indicating that the mechanism responsible for the 
reduction of ∆Np63α  protein, was independent from both p53 and MDM2.  
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In order to verify to what extent Dlx3 was altering ∆Np63α protein level, I measured 
∆Np63α protein half-life in Saos2 cells, with or without Dlx3, by treating cells with 
Figure 10. Dlx3 reduces p63 protein level.  
(A) NHEK stable cell lines were induced for Dlx3 expression and cellular lysate were analyzed for ∆Np63α 
expression. (B) Western Blot analysis of HaCaT  cell extracts 48 hrs upon transfection  with increasing amounts
(0.5; 1.0 and 1.5 µg) of Flag tagged Dlx3 expression vector. Endogenous ∆Np63a was revealed with 4A4 
antibodies, Dlx3 with anti-Flag antibodies. Actin was checked as loading control. (C) Saos2 cells were
cotransfected with 0.2 µg of ∆N or TAp63α  plasmid DNA and increasing amounts (0.5; 1.0 and 1.5 µg) of Flag-
Dlx3 expression vector. 48 hrs after transfection cell extracts were analyzed by Western blot and specific 
immunodetection. RT-PCR. Level of exogenous ∆Np63α  mRNA upon cotransfection with increasing amount ( 
1.0 and 1.5µg) of Dlx3-Flag expression plasmid in Saos2 cells.  (D) Mouse Embryo Fibroblasts (p53-/- MDM2-/-
) were transfected with 0.2 µg of ∆Np63α alone or together with 1.0 µg of Flag-Dlx3 expression vector. At 48 hrs 
after transfection cell extracts were analyzed by Western blot and specific immunodetection.   57
the protein synthesis inhibitor cycloheximide. I transfected Saos2 cells with p63 
encoding vector alone or with Dlx3 expression plasmid, and 16 hours after 
transfection, cells were treated with cycloheximide to block protein synthesis. At the 
indicated times after exposure to the drug, cells were harvested and the extracts 
analyzed by Western Blot and probed with an anti-p63 and anti-flag antibodies.  
Transfected ∆Np63α protein was very stable with a half-life being greater than 9 
hours; expression of Dlx3 reduced ∆Np63α protein level and the decay was faster, 
with a half-life between 5 to 7 hours ( fig. 11).   
 
 
 
Figure 11. Dlx3 affects ∆Np63α protein half-life.  
Saos2 cells were transfected with 0.2 µg of ∆Np63α, expression plasmid alone or along with a fixed
amount (1µg) of Dlx3-Flag encoding plasmid. 16 hours after transfection cells were treated with 40µg/ml
of  cycloheximide. At the indicated times, cells were lysated and cellular extract were analyzed by
Western Blot and specific immunodetection. Saos 2 cells were also transfected with Dlx3-Flag expression
plasmid alone to determine Dlx3 protein half-life.  58
As it has been reported that both proteasome and lysosome are involved in p63 
protein degradation (Ghioni et al. 2005, Rossi et al. 2006), I decided to investigate 
whether Dlx3-driven p63 degradation was proteasome or lysosome-dependent. 
Reduction of p63 by Dlx3 was efficiently reversed by the proteasome inhibitors 
MG132 and ALLnL while no effect was observed treating cells with the lysosome 
inhibitor chloroquine or ammonium chloride (Figure 12 A  and data not shown). 
Finally, to determine if a physical association between p63 and Dlx3 protein was 
required to induce p63 protein degradation, I immunoprecipitated ∆Np63α from 
lysates of Saos2 cells expressing p63, Dlx3 or both. Whole extracts were subjected to 
Western blot and specific immunodetection with anti-p63 (4A4) antibodies. Dlx3 was 
revealed with anti-Flag antibodies. I also performed the reciprocal experiment and, in 
both cases, I failed to see interaction between p63 and Dlx3 (Figure 12 B and data not 
shown). These data suggest that Dlx3 is activating a protein degradation pathway that 
leads to the reduction of p63 level and that this molecular mechanism does not 
require a direct interaction between the two proteins. 
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Figure 12. Dlx3 mediates proteasome-dependent degradation of p63 and its function does not
require p63-Dlx3 physical association. 
(A) Saos 2 cells were transfected with the expression vector for ∆Np63α ( 0.2µg) with or without a fixed amount
(1µg) of Dlx3 expression vector in the presence or absence of 10µM of MG132 or ALLnL. Total lysates were
separated by SDS-PAGE and blotted with antibodies against p63 ( 4A4) or Flag to detect Dlx3 protein. (B)
Coimmunoprecipitation of ∆Np63α with Dlx3. Saos2 cells were transfected with 0.2µg of ∆Np63α plasmid
alone or togheter with Dlx3-Flag expressing plasmid. Cellular extract were immunoprecipitated with anti p63
4A4 antibody and immunocomplex were analyzed with anti-p63 and anti-Flag antibodies.  
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2.2) Dlx3-induced ∆Np63 degradation requires specific Serine and Threonine 
residues located in the p63 α and β carboxyterminal tails.  
 
 Although ∆Np63α is the most abundantly expressed p63 isoform in adult skin, I 
wished to investigate whether Dlx3 could also reduce the level of the remaining 
∆Np63 isoforms. Thus, I overexpressed ∆Np63β or γ, in Saos2 cells, along with 
increasing amount of Dlx3. Interestingly, the levels of ∆Np63β was significantly 
reduced by Dlx3 while ∆Np63γ was almost completely unaffected (Fig. 13 A). These 
results suggested that aminoacid residues located in the α and β tail of p63, could 
confer the sensitivity to the degradation mechanism triggered by Dlx3 expression. To 
identify these residues , I tested two constructs expressing carboxyterminal truncated 
∆Np63 proteins, named ∆Np63∆408 and ∆373 (a schematic representation is shown 
in Fig. 12 B), kindly provided by Dr. Guerrini ( University of Milan). I transfected 
each of them into Saos2 cells, with or without Dlx3 and compared with wild type 
∆Np63α for the sensitivity to Dlx3-mediated degradation. Interestingly, the 
∆Np63α∆373 protein was almost unaffected by Dlx3, while ∆Np63α∆408 was 
efficiently degraded (Fig. 13 B).  
Thus, I concentrated my attention on the region encompassing aminoacid 373 to 408 
of ∆Np63; by the NetPhos 2.0 bioinformatic analysis I identified two potential 
phosphoacceptor sites, located in this region, a Serine at position 383 (score 0.866) 
and a Threonine at position 397 (score 0.6). Furthermore, using the ELM 
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bioinformatic resource (http://www.elm.eu.org), we found that  Serine383 was 
included in a PIKK (PI3K related kinases) phosphorylation motif, while Threonine 
397 was a potential MAPK phosphorylation site. Interestingly, Serine383 and 
Threonine397 also belong to the Phospho Cluster IV, as described by Finlan and 
Hupp (Lee E. Finlan and Ted R. Hupp; 2007). In the laboratory of  Dr. Guerrini at the 
University of Milan it was generated, by site-directed mutagenesis, the 
∆Np63αS383A construct bearing a Serine to Alanine substitution at position 383 and 
the ∆Np63αT397A expression plasmid, bearing a Threonine to Alanine substitution 
at position 397. Strikingly, substitution of either Ser383 or Thr397 caused a 
remarkable decrease of  ∆Np63α sensitivity to Dlx3-driven degradation (Figure 13 
B). In addition, it was generated the ∆Np63αS383AT397A protein bearing both 
aminoacid substitutions. As expected, the S383T397 double mutant was almost 
completely resistant to Dlx3-mediated degradation (Figure  13 B). These results 
indicate that the mechanism through which Dlx3 causes p63 protein degradation is 
dependent on specific serine/threonine residues located in the p63 carboxyterminal α 
and β tails. Consistently, ∆Np63γ lacking these residues, was almost completely 
refractory to Dlx3-induced degradation (Figure 13 B).  
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Figure 13. Carboxyterminal α and β tails of p63 confer to ∆Np63 sensitivity to Dlx3 elicited
degradation.  
(A)  ∆Np63α, β and γwere compared for their sensitivity to Dlx3-mediated degradation by cotransfection and
immunoblot experiments in Saos2 cells. for their sensitivity to dlx3-mediated degradation by cotransfection
and immunoblot experiments in Saos2 cells. 0.2 µg of p63 expression vectors were transfected in Saos2 cells
along with increasing amount of Dlx3 plasmid (0.5, 1.0 and 1.5 µg). P63 and dlx3 were revealed with 4A4 and
anti-Flag antibodies, respectively. ( B) Schematic representation indicating the positions where stop codons
were inserted to generate the ∆373, ∆390 and ∆408 truncated version of ∆Np63α , the Ser383 and Thr397 that
have been replaced with Alanine have also been indicated. ∆Np63α was compared with deletion (∆373, ∆390
and ∆408)  and point mutants (∆NaS383A, ∆Np63αT397A, and ∆NαS383T397A)  for their sensitivity to
Dlx3-mediated degradation. 0.2 µg of each ∆Np63α construct was transfected in Saos 2 cells along with
increasing amount of Dlx3 plasmid (0.5, 1.0 and 1.5 µg). P63 and dlx3 were revealed with 4A4 and anti-Flag
antibodies, respectively. Actin was used as a loading control.  63
To confirm that S383 and T397 were involved in Dlx3-mediated p63 degradation  I 
expressed the ∆Np63αS383AT397A double mutant in Saos2 cells, with or without 
Dlx3, and measured p63 protein half-life in cycloheximide-treated cells.  The half-life 
of ∆Np63αS383AT397A mutant, in presence of Dlx3, was greater than 9 hours 
(Fig.14) while that of the wild type protein was among 5 and 6 hours (Figure 11) 
implying that Dlx3-induced p63 protein degradation was impaired preventing 
phosphorylation of Serine383 and Threonine397.  On the other hand, ∆Np63αS383A 
and ∆Np63αT397A proteins also exhibited increased half-life in presence of Dlx3, 
confirming that both residues were involved in the mechanism of Dlx3-mediated p63 
degradation (data not shown). Next, I tested if replacement of Serine383 and 
Threonine397 with Alanine, was dramatically changing their subcellular localization. 
To answer this question I performed immunofluorescence microscopy and I could 
verify that the ∆Np63αS383AT397A protein was normally distributed into the 
nuclear compartment, both in absence and presence of Dlx3 exogenous expression 
(data not shown). 
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 Figure 14. The ∆Np63αS383AT397A mutant  increase half-life in presence of Dlx3. 
Saos2 cells were transfected  with the ∆Np63αS383AT397A double mutant with or without 
Dlx3, and p63 protein half-life was measured in cycloheximide-treated cells ( 40µg/ml). At 
the indicated times, cells were lysated and cellular extract were analyzed by Western Blot 
and specific immunodetection. 65
2.3) Dlx3-mediated p63 degradation is impaired by inhibiting Raf signaling 
pathway.  
 
Dlx3 is induced in primary mouse keratinocyte by increasing the level of 
extracellular calcium and in parallels a reduction of  ∆Np63α protein is observed 
(Radoja N. et al. 2007). As substitution of Threonine397 and Serine383 with Alanine 
prevented the reduction of  ∆Np63α protein level upon Dlx3 transfection, we 
hypothesized that phosphorylation of these specific residues was a prerequisite for 
Dlx3-induced ∆Np63α protein degradation. Park and Morasso reported that Dlx3 is 
activated through a protein kinase C-dependent (PKC) pathway (Park GT and 
Morasso MI; 2001). As PKC can signal to MAP kinases  through Raf1 ( Seo HR et 
al; 2004) I examined the status of the Raf signalling major components upon 
transfection of increasing amount of Dlx3 in HaCaT keratinocytes. By using 
antibodies that specifically recognize the phosphorylated active forms of Raf1 and 
MAPKs (ERKs and p38MAPK) I found that phosphorylated Raf1 and ERKs 
increased markedly in response to Dlx3 expression (Figure 15). By contrast, 
phosphorylated p38MAPK was reduced (Figure 15). Similar results were obtained in 
Saos2 cells (data not shown). I examined the possible contribution of Raf and the 
other components of its pathway on Dlx3-mediated p63 degradation by using specific 
pharmacological inhibitors ( figure 16 ). I transfected Saos2 cells with a fixed amount 
of p63 and Dlx3 expression vectors exposed to 10µM GW5074 for 3, 6 and 8 hours. 
As shown in Figure 16 B, incubation of cells with GW5074, a specific Raf inhibitor, 
resulted in a substantial recover of p63 protein levels and a clear decrease of Dlx3 
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protein level suggesting that p63 degradation, induced by Dlx3, was mediated by Raf 
activity. It has to be noted that incubation of cells with GW5074 did not result in 
change of  ∆Np63α level if ∆Np63α was transfected without Dlx3. However, as 
shown in figure 16 D, treatment of p63 and Dlx3 transfected Saos2 cells with 
PD98059, the specific ERK inhibitor, appears to reduce exogenous p63 protein level 
when ∆Np63α was transfected both alone and with Dlx3. This observation suggests 
that ERKs are involved in a pathway of p63 protection independently from Dlx3. 
Conversely, specific inhibition of p38MAPK with SB203580 had absolutely no effect 
on dlx3-mediated p63 degradation (Figure 16 C).  
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Figure 15. Raf1 and ERKs increased markedly in response to Dlx3 expression. 
HaCat cells were transfected with an increasing amount ( 1  and 1.5µg) of Dlx3-Flag
expression plasmid. 24 hours after transfection, cells were lysate and extract was
analyzed by Western Blot analysis and immunodetection with specific antibodies. 68
  
 
 
 
 
 
 
 
 
 
 Figure16. Dlx3-mediated p63 degradation is impaired by inhibiting Raf signaling pathway. (A)
Schematic representation of specific pharmacological inhibitors of the Raf signalling pathway and their
target . (B)  Saos2 cells were transfected with p63 encoding plasmid (0.2µg) alone or togheter with a
fixed amount ( 1µg) of Dlx3-Flag expression plasmid. 16 hours after transfection cells were treated with
10µM of GW5074. At the indicated the indicated times, cells were lysated and cellular extract were
analyzed by Western Blot and specific immunodetection. 
(C)  Saos2 cells transfected with p63alone or along with Dlx3 were treated  for 15 hours with two
different amount ( 25 and 50µM) of SB203580, a specific p38MAPK inhibitor and (D) with a fixed
amount ( 50µM) of PD98059, a specific ERKs inhibitors. Cells were lysated and extract was analyzed by
Western Blot and specific immunodetection.  
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To further explore the role of Raf kinase activity in p63 degradation induced by Dlx3, 
I transfected, in Saos2 cells,  increasing amount of a construct expressing the kinase 
active domain of Raf1, Raf(BxB) (Pearson et al. JBC 2000), with a fixed amount of 
Dlx3. As shown in Figure 17 B, coexpression of Dlx3 with activated Raf resulted in a 
dose-dependent increase of Dlx3 protein level and, as expected, in a significant 
increase of phosphorilated ERKs. Moreover, when we transfected Saos2 cells with 
Raf BxB and ∆Np63α along with a fixed amount of Dlx3 I observed again an 
increase of Dlx3 protein and a more pronounced ∆Np63α protein degradation ( fig. 
17 A). Interestingly, in absence of Dlx3, Raf BxB seems to cause an increase of  the 
∆Np63α ( fig. 17 A) . This effect might, presumably, be the conseguence of  ERKs 
activation upon transfection of constitutively activated Raf BxB. Altogheter, these 
observations suggested that the effect of activated Raf on p63 protein levels was 
actually dependent on Dlx3. To confirm the relevance of Serine 383 and Threonine 
397 of ∆Np63α in Dlx3-induced p63 degradation, I transfected the 
∆Np63αS383AT397A mutant protein with a fixed amount of Dlx3 and increasing 
amounts of Raf(BxB).  As shown in Figure 17 C, despite the remarkable increase of 
Dlx3 level caused by Raf(BxB) coexpression, the p63 double mutant protein 
remained unaffected.  
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 Figure 17. Involvment of Raf kinase activity in Dlx3-induced p63 degradation. 
(A) Raf BxB increase Dlx3-dependent p63 degradation. Saos 2 cells were transfected with a fixed
amount ( 0.2µg) of p63 expression plasmid alone ( lane 1),  p63 and increasing amount ( 0.5, 1, 1.5µg)
of Dlx3-Flag expression plasmid ( lanes 2-4), p63 and increasing amount ( 0.5,1,1.5µg)  of Raf BxB (
lanes 5-7), p63 with a fixed amount ( 1µg)  of Dlx3( lane 8)  and increasing amount (1and1.5µg)  of
RafBxB ( lanes 9and 10). 24 hours after transfection cells were lysated and cellular extract was
analyzed by Western Blot and specific immunodetection. (B) Effect of Raf BxB on Dlx3 expression
levels. Saos2 cells were transfected with a fixed amount ( 1µg) of Dlx3-Flag encoding plasmid alone
and along with increasing amount ( 1 and 1.5µg) of RafBxB expression plasmid. 24 hours after
transfection cells were lysated and extract aanalyzed by Western Blot. (C) The ∆Np63αS383AT397A
mutant protein  is unaffected by coexpression of Dlx3 and Raf BxB. Saos 2 cells were transfected with
a fixed amount ( 0.2µg) of ∆Np63αS383AT397A expression plasmid alone ( lane 1),  mutant p63 and 
increasing amount ( 0.5, 1, 1.5µg) of Dlx3-Flag expression plasmid ( lanes 2-4), mutant p63 and
increasing amount ( 0.5,1,1.5µg)  of Raf BxB ( lanes 5-7), mutant p63 with a fixed amount ( 1µg)  of
Dlx3( lane 8)  and increasing amount (1and1.5µg)  of RafBxB ( lanes 9and 10). 24 hours after
transfection cells were lysated and cellular extract was analyzed by Western Blot and specific
immunodetection 71
Finally I sought to determine whether  p63 natural mutants associated to distinct 
human hereditary syndromes, exhibited different sensitivity to dlx3-mediated 
degradation. I tested the ∆Np63αK194E and ∆Np63αQ639X mutants both derived 
from Split Hand and Foot Malformation 4 (SHFM4), as well as the  the Hay-Wells 
syndrome derived ∆Np63αQ540L and the EEC-derived ∆Np63αC306R. Actually, all 
of the mentioned mutants were efficiently degraded by Dlx3 ( fig. 18). 
 
 
 
  
 
 
Figure 18. p63 natural mutants associated to distinct sindrome were efficiently degraded by Dlx3. 
Saos2 were transfected with different p63 mutant constructs alone or with increasing amount ( 0.5,1 and 
1.5µg) of Dlx3-Flag expression plasmid. 24 hours after transfection cells were lysate and extract analyzed
by Western Blot and specific immunodetection. 
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3 ) Investigation on mechanisms throught which p14ARF regulates p63 
transcriptional activity. 
 
Recently, in the lab where I worked it has been demonstrated that there is a physical 
and functional relationship  between p63 and p14ARF. First, already pubblished data 
( Calabrò et al; 2004)  indicate that, unlike p53, p63 is able to associate with p14ARF, 
both in TA and ∆N version, in different mammalian cell lines. Remarkably, 
overexpression of TAp63, but not ∆N, promotes the exclusion of p14ARF from the 
nucleus. Finally, p14ARF inhibits both transactivation and transrepression activity. 
To better investigate the mechanism throught which ARF inhibits p63-driven-
transcription, I decided to examine whether p14ARF was able to impair the binding 
of p63 to a canonical p53 consensus sequence. EMSA experiments gave preliminary 
indications that  p14ARF was able to decrease the binding of p63 to p53 consensus 
sequence. To gain further  insights in this mechanism I performed Chromatin Ip 
assays to test the effect of ARF on the p63 DNA binding activity on different p53 and 
p63 target gene promoters. For ChIP analysis, I transfected H1299 cells with p63 
alone or along p14ARF expression plasmid. Formaldeyde cross-linked chromatin was 
immunoprecipitated with anti-p63 4A4 antibody. Eluted DNA was PCR amplified 
with specific primers for different p63 ( JAG 2, DLX 3) and p53 ( p21WAF, 14-3-3σ 
) target promoters. As shown in figure 17, when cotransfected with p14ARF, 
TAp63α appeared to bind to the tested promoters with a lower affinity. This effect 
was less evident with ∆Np63α isoform. To confirm the specificity of this effect, I 
transfected H1299 cells with p53 and p14ARF expression plasmids and I 
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immunoprecipitated the chromatin with anti p53 antibody.  PCR analysis of p21WAF 
promoter showed that ARF does not affect  p53 DNA binding activity in this 
experimental condition.  
My results suggest that when coexpressed, ARF is able to modify the DNA binding 
activity of p63 on different promoters thereby it might potentially alter the pattern of 
expression of genes regulated by p63. 
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Figure 17. p14ARF impairs DNA binding ability of p63. H1299 cells were transfected with p63 alone or with 
p14ARF expression plasmids. Formaldeyde cross-linked chromatin was immunoprecipitated with anti-p63 4A4 
antibody. Eluted DNA was PCR amplified with primers specific for different p63 ( JAG 2, DLX 3) and p53 (
p21WAF, 14-3-3σ) target promoters genes. H1299 cells were also transfected with p53 alone or with p14ARF 
encoding plasmids and chromatin immunoprecipitated with anti p53 antibody.  Eluted DNA was PCR amplified
with primers specific for p21WAF promoter. 
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I have also performed experiments to better define the region of p63 required for the 
physical association with ARF. Previously, it has been demonstrated that p63-
p14ARF interaction requires the first 38 N-terminal aminoacids of p14ARF and the 
first 26 aminoacids of ∆Np63α. Twelve aminoacids ( encompassing 15 to 26 of 
∆Np63 and 109 to 120 of TAp63) among the first 26 aminoterminal residues of 
∆Np63α ( TA2 domain), are in common between TA and  ∆N p63 isoforms. We 
have supposed that this stretch of 12 aminoacids contains residues that might be 
crucial for p63-p14ARF association. To better identify the region that mediates the 
interaction I took advantage of some natural occurring p63 mutations. In particular, I 
used the G76W point mutation that is found in Limb Mammary Sindrome (LMS) 
affected patients, that falls in the region under study and, precisely, in the TA2 
domain of p63 ( fig. 18A).  The mutation was inserted both in the TA and 
∆Nα isoforms and tested for the interaction with ARF. Both TA and ∆Nα isoform 
carrying  the G76W point mutation were a kind gift of Dr. Hans vonBokhoven. I 
transfected NIH3T3, a murine ARF-/- cell line, with plasmid encoding the different 
p63 constructs alone or in combination with a plasmid encoding p14ARF. Cellular 
extracts were immunoprecipitated with an antibody against p14ARF, blotted and 
incubated with anti p63 and anti ARF antibody. As shown in figure 18 B, while the 
G76W substitution completely impairs the ability of  ∆Np63 to bind ARF protein, the 
TA isoform retains the ability to interact with ARF suggesting that  TA1 and TA2 
domains could contain regions involved in p63-p14ARF association.  
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Figure 18. Identification of p63 domains involved in p14ARF interaction. a) Schematic representation of
the p63 G76Wmutant construct. b) NIH3T3 cells were transfected with 1µg of expression plasmids encoding
wild-type TAp63α, ∆Np63α or the indicated p63 mutant isoforms alone or togheter with 2µg of p14ARF
expressing plasmid. Cellular extracts were immunoprecipitated with anti-p14ARF antibody and
immunorevealed with anti-p63. 
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Discussion 
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Epithelial development and differentiation in embryo rely on a set of temporally and 
spatially regulated molecular events. Recent observations designate p63 as a driving 
force of this process: the ∆Np63α isoform maintains the proliferative potential of 
basal keratinocytes in mature epidermis, whereas the TAp63α isoform is believed to 
act as a molecular switch required for commitment to epithelial stratification.The 
existence of malformations due to p63 gene mutations suggests that this gene might 
be component of signaling cascades regulating epidermal and ectodermal appendage 
development. The severity of the phenotype in p63-null mice suggests that it is an 
upstream crucial regulator of these signaling pathway. A broad spectrum of p63 
mutations are responsible for several human ectodermal, craniofacial and limb 
malformation. EEC and ADULT mutations are located in the DB domain of p63. 
They abolish p63 DNA-binding and produce higly stable, but transactivation-inert 
TAp63 proteins ( Ying et al; 2005). AEC mutations are confined to the SAM domain. 
Their effect on p63 transcriptional functions are less predictable and they only affect 
the α isoforms.  
Very few genes that are directly regulated by p63 to modulate differentiation and 
very few p63 protein partners that could modulate its transcriptional activity are 
currently known. Therefore, during my doctoral studies I have explored some of the 
molecular pathways that regulate p63 protein function. First, I decided to identify p63 
specific transcriptional targets that were relevant for the pathogenesis of human AEC 
syndromes.  
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The Q540L mutation impairs p63 transcriptional ability. 
My studies provides evidence that the Q540L amino acid substitution strongly 
impairs the transcriptional activity of TAp63α. 
Our genome-wide transcriptional profiles comparing the transcriptional response 
induced by wt and TAp63αQ540L expression show that 14 out of 45 differentially 
modulated probe sets (ten annotated genes), are characterized by a loss of control 
(activation or repression) by the Q540L mutant. As indicate by my reported 
experiments, the lack of transactivation ability of TAp63αQ540L cannot be attributed 
to a decrease in its expression, nor to alteration of its subcellular location. It is well 
documented that, p63, like p73, can bind to the p53 consensus DNA-binding motif 
and activate a number of p53-regulated genes. In principle, the Q540L mutation, even 
though it is predicted to not destroy the overall structure of the SAM domain, could 
alter the DNA-binding affinity of the mutant protein. As regulation of p21/WAF was 
severely impaired in cells expressing the Q540L mutant, I tested whether the mutant 
protein was still capable of interacting with a p53-binding motif of the p21/WAF 
promoter. My results indicate that both wt TAp63α and its Q540L mutant are equally 
active in binding to this sequence, in our in vitro system. However, my data obtained 
through ChIP assays indicate that the Q540L mutation affects the ability of p63 to 
bind its target promoters in a chromatin context. A possible explanation is that such 
mutation might affect the binding of p63 to a particular coactivator that could 
increase the affinity of the protein for its target promoters. The observation that the 
binding to p21/WAF, IKK, JAG and Dlx3 promoters is affected by the AEC-derived 
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mutation suggest that a common factor is required for the control of the expression of 
these genes by p63. For instance, it has been reported that Sp1 cooperates with p53, 
p63 and p73 in synergistic transactivation of the p21/WAF promoter.36 and my data 
clearly indicate that TAp63Q540L is still able to interact with Sp1 (Fig. 6B). Other 
transcriptional factors may thus be crucial for p63-driven transcription and the Q540L 
amino acid substitution may affect the interaction between the p63 SAM domain and 
a still undefined factor.  
Finally, microarray analysis has revealed that specific probe sets are up or down-
regulated by the mutant protein alone. These seemingly conflictual results might 
again be explained as a consequence of a loss of transcriptional function 
assuming that the above mentioned genes are p63 secondary targets, which are 
repressed or activated by p63 primary targets.  Alternatively, we cannot exclude 
that the Q540L aminoacid substitution confers new transcriptional regulative 
properties to the TAp63α protein altering its affinity to interact with particular 
coactivators or corepressors.  
Differentially expressed genes and their implication in AEC pathogenesis. An 
extensive search of the published literature to find links between the physiological 
functions of the deregulated genes and their role in AEC showed that, with the 
exception of p21/WAF and MDM2, they were the subject of very few publications 
and littlewas known about their functions. It was, however, found that GDF15, 
BVES, CLMN and CPM are involved in the mechanisms of cell differentiation,42-45 
while ARX and FGF5 are associated with embryonic development ( Clase KL et al; 
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2000; Collombat et al; 2003; Yoshihara et al; 2005).  GDF15 is the murine ortholog 
of the human immunoregulatory cytokine macrophage inhibitory cytokine-1 (MIC-1) 
also known as PDF (prostate derived factor), a divergent TGF-β superfamily 
member. It has proapoptotic and antimitotic activities and is involved in the control 
of prostatic cell growth ( Uchida et al; 2003). Interestingly, the GDF15 promoter 
contains two putative p53 responsive elements and is upregulated by p53, though its 
expression in response to injury also appears to be induced p53-independently.50,51 
GDF15 seems to be a p63 target, specifically upregulated by TAp63. This regulation 
is completely abolished by the Q540L amino acid substitution. The lack of GDF15 
expression in epithelia may contribute to the abnormal differentiation of epithelia-
derived structures observed in AEC patients. 
Another gene closely involved in development is ARX ( Collombat et al; 2003). Its 
expression profile is highly complex and dynamic in the mouse embryo brain, where 
it peaks at embryonic (E) day 9.5 just after the TAp63α expression peak (E. 8.5).3 It 
is also a marker of adult neuronal stem cells( Collombat et al; 2003). Interestingly, 
both TAp63α and ARX transcripts decrease at E 13.5, which corresponds to the 
switch from TAp63α to ∆Np63α expression ( Koster et al; 2004). Our transcriptional 
profiling combined with the published data on ARX suggests that p63 and ARX may 
be linked in a common regulatory pathway. The information available, however, is 
not sufficient to allow a direct connection to be made between the function of p63 
and ARX in AEC. Calmin (CLMN) is a protein with calponin homology (CH 
domain) and transmembrane domains expressed in maturing spermatogenic cells. The 
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cDNA encoding CLMN was isolated by RNA differential display applied to 
developing mouse skin. The region covering the CH domain showed a high level of 
homology with β-spectrin, α-actinin, and dystrophin. The CLMN transcript was 
detected in adult testis, liver, kidney, and large intestine; the expression in testis was 
by far the strongest ( Ishisaki et al; 2001). CLMN is linked to skin development. In 
mice, its mRNA starts to be detectable in the epidermis at 15.5–16.5 dpc (days post-
coitum) and its expression increases as theskin develops. The timing of CLMN gene 
expression corresponds to the switch from the TA to the ∆N isoform. CLMN is only 
transactivated by the Q540L mutant. Since induction of CLMN expression fits in 
nicely with the timing of the switch from TAp63α to ∆Np63α expression in the 
epithelial stratification program ( Koster et al; 2004), TAp63α may be supposed to 
act as a transcriptional repressor of this gene, with the result that expression of mutant 
TAp63α might improperly anticipate CLMN expression during skin development.  
BVES/Pop1 is the prototype of a new class of cell adhesion molecules. It is expressed 
in the epithelial components of retina, lens and cornea ( Ripley et al; 2004), during 
blood vessel development, in the gut endoderm and the epicardium and in all three 
germ layers during avian organogenesis ( Osler et al; 2004). BVES is transactivated 
by TAp63α and not modulated by the Q540L mutant, and hence may be required to 
promote cell adhesion and translocation during early embryogenesis.  
Another interesting gene that is only transactivated by the mutant p63 is SERPINH1, 
also known as HSP47. Hsp47 protein is involved in skin wound regeneration and 
immunohistochemistry has demonstrated Hsp47-positive cells in the epidermal cell 
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layer of fetal and neonatal rat skin. Hsp47 may be an important determinant of scar 
formation, since scarless healing of fetal skin wounds correlates with a lack of change 
in HSP47 expression ( Wang et al; 2002).  p21/WAF has long been known to arrest 
the cell cycle. In the epithelium it is involved in maintenance of the stem cell 
compartment ( Okuyama et al; 2004). 
p21 null mice are unable to limit the production of stem cells and their proliferative 
potential.55 p21/WAF is strongly transactivated by the TAα wild-type isoform and 
its promoter is not or only mildly responsive to the ∆Nα isoform (Westfall et al; 
2003).  By inducing p21/WAF, TAp63α breaks the cell cycle by restraining stem cell 
proliferation: the overall system is committed to the formation of stratified epithelia. 
The parallel increase of ∆Nα and decrease of TAp63α expression redirects the 
system to terminal differentiation ( Westfall et al; 2003).  Our qPCR data and 
expression studies support this scenario since the p21/WAF promoter is strongly 
activated by the TAp63α wt isoform and p21/WAF upmodulation is reduced if 
∆Np63α is expressed. Interestingly, while ∆Np63α seems less efficient than 
TAp63α as a p21/WAF activator, they both induce a similar G1 cell cycle arrest. The 
aminoterminal-deleted isoform should not be generally defined as a transactivation-
defective isoform. Our and other published data indicate that ∆Np63α modulates 
transcription40 and this ability is rather dependent on the specific gene promoter. In 
conclusion, the difference in the growth rate profiles of cells expressing either the TA 
or the ∆Np63α isoforms is likely to be the result of the relatively higher efficiency of 
TAp63α with respect to ∆Np63α in inducing cell death.  
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The growth rate profiles and cell cycle distribution of cells expressing the AEC-
derived TAp63α protein are undistinguishable from those of uninduced cells, 
indicating that the Q540L amino acid substitution affects both the cell cycle arrest 
and cell death inducing properties of p63. Finally, we suggest that deregulation of 
p21/WAF associated with the Q540L mutation will produce a defect in the process of 
commitment to epithelial stratification that simultaneously allows premature 
expression of skin differentiative markers. A defect of this kind would explain the 
skin fragility and chronic scalp erosions complicated by infections, which are a 
hallmark of AEC. In conclusion, further investigation of the differentially regulated 
genes identified in this study will result in a better understanding of the molecular 
mechanism underlying the AEC phenotype. 
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Dlx3 regulates p63 protein levels. 
AEC-derived TAp63 proteins and in particular the Q540L mutant exhibits an 
impaired ability to transactivate Dlx3, thus suggesting that the misregulation of the 
Dlx3 gene is involved in the pathogenesis of AEC.  
The Dlx3 gene, a target of p63, is expressed in the suprabasal layer of skin. 
Expression of Dlx3 in keratinocyte is activated, through a PKC-dependent pathway, 
by increasing the level of extracellular Ca2+. The increase of extracellular Ca2+ is an 
important trigger of epidermal terminal differentiation that contributes to the decrease 
of ∆Np63α expression by reducing ∆Np63α gene transcription (Radoja et al; 2007   
). My reported data indicate that Dlx3 reduces also protein half-life and steady-state 
levels. I have observed this phenomenon in several cell contexts, including  p53-/- 
and MDM2-/- mouse fibroblasts indicating that neither p53 nor MDM2 were 
involved in this mechanism. Interestingly, Dlx3 overexpression resulted in efficient 
∆Np63α/β, but not γ, protein degradation. The evidence that ∆Np63γ is completely 
resistant to Dlx3-mediated degradation means that residues located exclusively in the 
p63 α and β, but not in the γ tail, are absolutely required for the mechanism of Dlx3-
mediated p63 degradation. Although I have not provided direct evidence that Ser383 
and Thr397 are phosphorylated upon Dlx3 expression, I have shown that their 
substitution with alanine impairs Dlx3-mediated ∆Np63α degradation, thus 
demonstrating that these residues are relevant for this phnomenon. However, I cannot 
rule out the hypothesis that additional serine/threonine residues may also have a 
minor contribution to this mechanism. Furthermore, I have observed that TAp63α 
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appears to be more resistant than the corresponding ∆N isoform, thus suggesting that 
the N-terminal region of p63 in some way interferes either with the phosphorylation 
or degradation mechanism of p63, possibly due to the minor accessibility of the 
TAp63α three-dimensional conformation. TAp63α expression  is completely absent 
in the basal layer of epidermis while it becomes detectable in the soprabasal layers of 
epidermis where it contributes to activate Dlx3 gene expression. Interestingly, my 
observation that TAp63α shows a lower sensitivity to Dlx3-mediated degradation 
compared to ∆Np63α, provides a possible explanation to its persistence in the 
granular layer of epidermis where Dlx3 is actually expressed. Moreover, since 
terminally differentiated keratinocytes lack completely p63 expression I can speculate 
that Dlx3 might also contribute to TAp63α protein degradation.  
Multisite phosphorylation is a common feature of many protein kinase substrates, 
which may enable docking interactions, integration of different kinase pathway 
signals or changes in the subcellular localization. Concerning this aspect, we have 
been able to exclude that substitution of serine 383 and treonine 397 with alanine 
could cause differences in the subcellular localization of p63, either in absence or 
presence of Dlx3 expression.  
Interestingly, I have shown a direct involvement of Raf1 in Dlx3-mediated p63 
degradation. Pharmacological inhibition of Raf activity was able to partially restore 
the basal level of p63 that was reduced upon Dlx3 expression. Moreover, the 
constitutively activated Raf was able to increase p63 degradation induced by Dlx3. 
On the basis of my data, I cannot conclude that Raf1 is the kinase responsible for p63 
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phosphorylation, however I have provided evidences that constitutively activated Raf 
enhances the levels of Dlx3 protein indicating at least one mechanism, strictly 
depending on Raf activity, that might significantly contribute to p63 protein 
degradation. In addition to Raf1 phosphorylation I have observed considerable 
increase of phosphorylated ERKs upon Dlx3 transfection. Activation of Raf1 by Dlx3 
can signal to ERKs through MEK kinases. Normal human epidermal keratinocytes 
(NHEK) respond to the autocrine activated ERK signaling pathway, which 
contributes to the survival of keratinocytes. According to the proposed pro-survival 
role for ERKs, it has been demonstrated that autocrine ERK activation, at early stage 
of differentiation, plays a role in the regulation of cell cycle rather than the expression 
of the keratinocyte differentiation markers ( Park et al; 2006).  Autocrine activation 
of ERKs is not interrupted by calcium-induced differentiation but it rapidly declines 
in absence of EGFR ligands (Park et al; 2006). We speculate that Dlx3 while 
inducing p63 degradation  might substain ERKs activation thereby delaying 
keratinocyte terminal differentiation. Alternatively, activation of ERKs might 
counteract apoptotic stimuli triggered by the detachment of keratinocytes from the 
epidermal basal layer as long as they move in the suprabasal layer of epidermis (   ). 
On the other side, we have found that ERKs inhibition enhances p63 protein 
degradation, confirming that ERKs activation protects ∆Np63α thus playing a 
positive role on keratinocyte survival during differentiation (Park et al; 2007). 
The Raf kinase activity appears to play a crucial role in epidermal differentiation 
being at the cross road between signals driving cell proliferation and differentiation. 
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The mammalian Raf family of serine/threonine kinases consists of three highly 
conserved members, i.e., A-Raf, B-Raf and Raf1 (Hagemann et al; 1999). Whereas 
Raf1 is ubiquitously expressed, A-Raf and B-Raf display a more tissue-specific 
expression.  The role of Raf1 in the epidermal differentiation is demonstrated by the 
phenotype of Raf1 targeted knock-out mice. Mice homozygous for a hypomorphic 
Raf1 allele (Raf1tm1Zim) die during organogenesis. Only 5% of homozygotes are 
viable and display underdeveloped hair follicles, thin epidermis and abnormal 
epidermal layer morphology (  Mikula et al; 2001 ). Interestingly, they also show 
abnormal placental labyrinth morphology strongly reminding the phenotype of Dlx3 
null mice (Morasso et al; 1999 ). Our data indicate that Dlx3 induces Raf1 
phosphorylation and moreover that inhibition of Raf kinase activity impairs p63 
degradation. Although we cannot exclude the role of other member of the Raf family, 
Raf1 appears to be clearly involved. Further studies are currently in progress in our 
laboratory to understand the molecular mechanism through which Dlx3 activates 
Raf1 and to identify whether Raf1 or a different serine/threonine kinase is directly 
responsible for p63 phosphorylation.  
It has been already reported that  K194E and E639X mutations associated to Split 
Hand and Foot Malformation syndrome do not affect the ability of  TAp63 to 
transactivate Dlx3 ( Radoja et al; 2007). I have here reported that these substitutions 
do not alter the sensitivity of ∆Np63α to the Dlx3-dependent degradation. This is in 
agreement with the lack of skin phenotype of patients affected by SHFM syndrome. 
On the other side, the EEC-derived C306R mutation, located in the p63 DNA binding 
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domain, and the AEC-derived Q540L substitution, located in the p63 SAM domain, 
both affect the ability of p63 to transactivate a set of target genes, including Dlx3 
(Radoja  et al; 2007). Thus, since p63 lies upstream to Dlx3 in the molecular pathway 
leading to skin differentiation patients affected by EEC and AEC exhibit a severe 
skin phenotype.  
In conclusion, my data revealed the existence of a regulatory network between p63 
and Dlx3 providing new clues for thee understanding of the molecular mechanism 
underlying skin differentiation.  
Lastly, I have also investigated on the mechanism responsible for the p14ARF-
dependent counteraction of p63 transcriptional activity. My data suggest that 
overexpression of p14ARF  is able to inhibit the ability of p63 to bind to several 
promoters. Respect to previously reported data ( Calabrò et al; 2004)  my ChIP assays 
indicate that p14ARF contribute to the regulation of transcription of p63/p53 target 
genes in their natural setting, given the important role of chromatin structure in the 
regulation of gene expression. Moreover, my data clearly show that ARF impairs the 
binding of TA and ∆Np63α also to promoters specifically regulated by p63 and not 
by p53 ( such as Dlx3).  
Hence, we could speculate that under mitogenic stimuli p14ARF physically 
associates with TA and ∆Np63 isoforms removing them from p63/p53-responsive 
promoters kepting p63 proteins  inactive in a p63-p14ARF complex . This process 
might turn on p53 transcriptional function activating the p53-dependent checkpoint 
control. The physiological relevance of my observation need to be further 
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investigated. In particular, it will be necessary to verify my results in  keratinocyte 
cell culture.  
I have also reported that the G76W substitution associated to LMS syndrome abolish 
the ability of ∆Np63α, but not of TAp63α, to interact with p14ARF, confirming that 
residues located in the TA domain might increase the binding affinity between 
p14ARF and p63. Further work is necessary in order to estabilish the relevance of 
this finding for the comprehension of molecular mechanism responsible for the LMS 
syndrome,  
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Plasmids 
All of the p63 wild type cDNAs in the pcDNA3 vector were kindly provided by Dr. Hans van 
Bokhoven. The mutation Q540L was created in the lab of prof. Calogero in Turin by PCR, 
using the NdeI site-containing upstream primer, p63NdeI_FW (CCA TCT TCA TAT GGT 
AAC AGC TCC CCA CCT C) and the downstream primer p63NcoI_RW (ATC ATC CAT 
GGA GTA ATG CTC AAT CAG ATA GA) containing the NcoI site and the substitution A->T 
that introduces the mutation. The mutated fragment was replaced in the TAp63α wild type 
sequence, digested with NdeI/NcoI to generated the TAp63αQ540L sequence and then cloned 
in pcDNA3. 
To create the plasmids encoding the p63 proteins under the control of the rtTA responsive promoter 
the cDNA fragments were extracted from pcDNA using Hind III and Xba I, blunted and cloned into 
the pBIG-βgal Not I site. The pTet-On, pTK-Hyg, and pBIG-βgal constructs were provided by 
Clontech. The Bp100CAT and p21WAF/CAT reporter plasmids have already been described 
(Calabrò et al. 2002; Ghioni et al. 2002).  
Plasmids. Raf1(BxB) encoding plasmid was kindly provided by Dr. A. Costanzo. Plasmid encoding 
carboxyterminal truncated p63 proteins, the ∆Np63αS383A and Thr397A point mutants and the 
∆Np63αS383T397A double mutant were produced using the GeneEditor in vitro Site-Directed 
Mutagenesis System (Promega) following the manufacturer’s instruction in the lab of Dr. Guerrini 
in Milan.  
 
 
Cells culture, transfection and reporter  assays. 
Human lung carcinoma H1299 cells (p53 null, no p63 expression) were obtained from 
American Tissue Culture Collection and grown at 37°C in humidified 5% CO2 in DMEM 
medium supplemented with 10% fetal calf serum. H1299 cells (5x104) were plated and 
transfected by calcium-phosphate precipitation with 20 µg of pTet-On plasmid (Clontech). 48 
hrs after transfection, cells were selected adding G418 (100 mg/ml) to the colture media. After 
4 weeks, single G418-resistant clones (H1299-rtTA) were picked up and expanded. The 
presence of the rtTA regulator in G418-resistant clones was checked performing a β-
galactosidase assay on H1299-rtTA cell extracts after transient transfection with the pBGI-βgal 
empty construct with or without doxycyline (Sigma-aldrich) addition (1 µg/ml).    
Tet-On/TAp63α, Tet-On/∆Np63α, Tet-On/TAp63Q540L cell lines were produced as follows:  
7 x 104 H1299-rtTA cells were co-transfected with each of the pBIG-p63 constructs and the pTK-
Hygro vector (20 to 1 rate) by calcium-phosphate precipitation. 24 hrs after transfection each 
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100mm plate was splitted (1:2) and cells were selected adding 800 µg/ml of hygromycin (Sigma-
Aldrich). After 4 weeks, single hygro-resistant clones were picked up, expanded and subjected to 
the analysis of p63 inducible gene expression by Western blot and specific immunodetection. p63 
stable clones were maintained in DMEM medium supplemented with 10% Tet-Approved serum 
(Hyclone). CAT assays with the WAFCAT or BP100CAT reporter plasmids were performed as 
previously described (Calabrò et al. 2004).  
The human osteosarcoma-derived Saos2 cells were maintained in RPMI 1640 medium and 10% 
fetal calf serum. HaCaT, Hela, and U20S cells were grown in Dulbecco’s modified Eagle medium 
supplemented with 10% fetal bovine serum (Euroclone) at 37°C in a humidified atmosphere of 5% 
(v/v) CO2 in air. Cells seeded at a density of about 70% confluence were transfected with the 
indicated amount of expression vector with LipofectAMINE reagent (Life Technologies. Inc.) for 
H1299 or LipofectAMINE 2000 for Saos2, HeLa, HaCaT and U2OS. The total amount of 
transfected DNA was kept constant by using the “empty” expression vector when necessary. P63 
half-life was determined by addition of 40 µg/ml cycloheximide (Sigma), 16 hours upon 
transfection. MG132, ALLNL, Bafilomycin, NH4Cl and Chloroquine treatments were performed 
the day after transfection with 10 and 20 µM MG132, 10 and 20 µM ALLN, 100 nM bafilomycin 
A, 20 mM NH4Cl, 100 µM chloroquine or solvent alone for 6 hours. Pharmacological inhibition of 
serine/threonine kinases was obtained by adding 25 and 50µM PD98059 (Calbiochem), 25 and 
50µM SB203580 (Calbiochem), 5 and 10 µM GW5074 ( Calbiochem).  
 
 
CAT assay 
H1299 were transiently transfected with 2µg of p21/WAF-CAT reporter plasmid/dish alone or with 
different amounts of each p63 expressing plasmid ( 1, 2 or 3 µg). Cells were collected 48h after 
transfection; equal amounts of cell extracts ( 50µg), determined  by the Bradford method ( BioRad), 
were assayed for CAT activity using 0,1mCi of [14C] chloramphenicol and 4mM acetyl-CoA. 
Separeted products were detected and quantified by Phosphorimager and Quantity One software. 
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Growth rate analysis 
To determine the rate of cell growth, approximately 6 x 104 cells were seeded in 60 mm-
diameter plates in presence or absence of doxycycline (1µg/ml) for five days to regulate 
exogenous protein expression. Medium was replaced every 48 hrs. At the indicated time points, 
two plates were rinsed twice with PBS to remove dead cells and debris. Live cells on the plates 
were trypsinized and collected separately. Cells from each plate were counted three times using 
a Burker chamber. The average number of cells from two plates was used for determination of 
growth rate. 
 
 
DNA histogram analysis 
Cells were counted and seeded at 2 x 105/100mm plate with or without doxycycline (1µg/ml). 
At the indicated time points, live cells on the plates were trypsinized and both floating dead 
cells in the medium and trypsinized live were centrifuged and washed twice with PBS. 
Approximately 106 cells were incubated in 1 ml of 0.1% NaCitrato, 50 µg/ml propidium iodide  
(Sigma Chemical Co., St. Louis, MO, USA), 20 µg/ml RNase A and 0.1% Nonidet P-40. Cells 
were incubated for 40’ at RT in a dark box. Stained cells were analysed in a fluorescence-
activated cytometer (FACSCalibur-BD, Menlo Park, CA, USA) within 1 hr. Data on DNA cell-
content were acquired using the CellQuest program (Beckton-Dickinson) on 20000 total events 
at a rate of 150+/-50 events/second and the percentages of cells in the SubG1, G0-G1, S and 
G2-M phases were quantified with the ModFit software (Beckton-Dickinson). The percentage 
of dead cells/total cells was determined by the trypan blue dye staining. Briefly, aliquots of 
cells were mixed with an equal volume of 0.4% Trypan blue dye solution (Sigma Chemical 
Co., St. Louis, MO, USA) and incubated for 15’at RT. Stained (dead) and unstained (live) cells 
were counted using a hemocytometer and the percentage of dead cells/total cells was 
determined by scoring an average of over 300 cells, twice per plate. 
 
 
Subcellular immunolocalization assay  
Immunolocalization in Tet-On stable cell lines was performed on doxycycline (1µg/ml) induced or 
uninduced condition, 105cells/35mm plate were grown on micro cover glasses (BDH). 48 hrs after, 
cells were washed with cold phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde 
(Sigma-Aldrich), for 15’ at 4°C. For immunolocalization in Saos-2 cells, 5.0 x105 were plated in 35 
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mm dish and grown on micro cover glasses (BDH). At 24 hrs after induction or transfection with 
the indicated vectors, cells were washed with cold phosphate-buffered saline (PBS) and fixed with 
4% paraformaldehyde (Sigma) for 15 min at 4°C. Cells were permeabilized with ice-cold 0.1% 
Triton X-100 for 10 min and then washed with PBS. P63 or Dlx3 subcellular localization were 
determined by using a 1:200 dilution of a monoclonal antibody against p63 ( 4A4) or an anti-FLAG 
monoclonal antibody against Dlx3-Flag ( Sigma) diluted 1:2000. After extensive washing in PBS, 
the samples were incubated with a Cy3-conjugated anti-mouse immunoglobulin G 
(ImmunoResearch Laboratory) at room temperature for 30 min. After PBS washing, the cells were 
incubated with DAPI (4’,6’-diamidino-2-phenylindole; 10 mg/ml [Sigma-Aldrich]) for 3 min. After 
PBS washing, the glasses were mounted with Mowiol (Sigma-Aldrich) and examined under a 
fluorescence microscope (Nikon). Images were digitally processed by Adobe Photoshop software. 
After a rinse with PBS, fixed cells were permeabilized with ice-cold 0.1% Triton X-100 for 10 
min and rinsed again with PBS. Cells were than incubated with DAPI (4,6-diamidino-2-
phenylindole; 10mg/ml Sigma-Aldrich) for 3 min, and washed again with PBS. Finally, the 
glasses were mounted with Moviol (Sigma-Aldrich) and cells examined under a fluorescence 
microscope (Nikon). To detect p63 protein the H137 (Santa Cruz) and the CyTM 3-conjugated 
anti-rabbit IgG  (ImmunoResearch Laboratories) antibodies were used, at room temperature for 
30 min. Images were digitally processed using Adobe Photoshop software.  
 
Western immunoblot analysis 
At the indicated time after transfection cells were lysed in 10 mMTris-HCl (pH 7.5), 1 mM 
EDTA, 150 mM NaCl, 0,5% NP-40, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 
0.5% sodium deoxycholate, and protease inhibitors. Cell lysates were incubated on ice for 30 
min, and the extracts were centrifuged at 13,000 rpm for 10 min to remove cell debris. Protein 
concentrations were determined by the Bio-Rad protein assay. After the addition of 2x loading 
buffer (2% sodium dodecyl sulfate [SDS], 30% glycerol, 300 mM 96-mercaptoethanol, 100 
mM Tris-HCl [pH 6.8]), the samples were incubated at 95°C for 5 min and resolved by SDS-
polyacrylamide gel electrophoresis. Proteins were transferred to a polyvinylidene difluoride 
membrane (Millipore) and probed with the following primary antibodies MDM2 (SC-965; 
Santa Cruz); p63 (H137; Santa Cruz); p63 (4A4; Santa Cruz); anti p21/WAF1 (Ab-11, CP74; 
Neomarkers), actin (1-19; Santa Cruz); anti-goat IgG/HRP (Santa Cruz); anti-mouse IgG/HRP 
(Amersham); anti-rabbit IgG/HRP (Bio-Rad), anti-FLAG M2 (Sigma), anti-p-ERK (Cell 
Signaling), anti-p38 (Cell Signaling), anti-pp38 (Cell Signaling), anti-pRaf1 ( Cell Signaling), 
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anti-ppRaf1(Cell Signaling). Proteins were visualized by an enhanced chemiluminescence 
method (Amersham).  
Coimmunoprecipitations were carried out in Saos2 cells and in 5.0 x105 cells were plated in 60 
mm dishes and transfected with the indicated vectors. Cells were harvested 24 hrs post-
transfection, and cell lysates were prepared as described above. One mg of whole cell extract 
was precleared with 30 µl of protein A-agarose (50% slurry; Roche) and then incubated 
overnight at 4°C with 2µg of anti-p63 (4A4; Santa Cruz) at 4oC o.n.. Immunocomplexes were 
collected by incubation with protein A-agarose (Roche) at 4 o C for 4 hrs. The beads were 
washed with Co-IP buffer (50 mM Tris-HCl pH 7.5; 150 mM NaCl; 5 mM EDTA; 0.5% NP40; 
10% glycerol), resuspended in 2X loading buffer (Sigma) and loaded in a SDS-10% 
polyacrylamide gel.  Proteins were then transferred onto a PVDF membrane (Millipore) and 
probed with the indicated primary antibodies. Proteins were visualized with an enhanced 
chemiluminescence detection system (Amersham).  
 
EMSA 
EMSA experiments were performed as already described (Parisi, Pollice et al., 2002). P63 
proteins were in vitro translated by using TnT reticulocytes from Promega with 0.5 µg of p63 
plasmid DNA. Next, 10 µl of the individual reactions was used either for the binding reaction 
or for Western blot analysis. The probe is a radiolabeled oligonucleotide duplex containing a 
p53-binding site present in the p21 promoter (p21.1 described in Westfall, Mays et al., 2003). A 
100-fold molar excess of the same cold oligonucleotide or an oligonucleotide containing a 
consensus binding site for E2F1 was used for competition experiments. For the supershift anti-
p63 antibodies (4A4; SantaCruz) or unrelated polyclonal anti-p21 antibodies (C-19; SantaCruz) 
were used, adding them to the sample prior to the binding reaction (30 min in ice). 
 
Microarray sample preparation.  
Total RNA (ttlRNA) was extracted and purified from stably transfected H1299 cell lines using 
the Concert Cytoplasmic RNA Purification Reagent (Invitrogen, Carlsbad, CA) as suggested by 
the manufacturer. ttlRNAs were then quantified and inspected by Bioanalyzer (Agilent 
Technologies) analysis. cRNAs were generated and hybridized on 12 HGU133plus2 
Affymetrix DNA chips according to the Affymetrix protocol, ttlRNA (8 µg) was used for the 
preparation of double-stranded cDNA using the one cycle cDNA sysnthesis kit (Affymetrix, 
USA). The cDNA was then used as a template to synthesize a biotinylated cRNA (16 hrs, 
37°C) with the IVT kit (Affymetrix, USA). In vitro transcription products were purified with 
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the IVT cleanup module and approximately 35 µg of cRNA were treated with the 
fragmentation buffer (35 min at 94°C). Affymetrix 12 HGU133plus2 array chips were 
hybridized with biotinylated cRNA (20 µg/chip, 16 hrs, 45°C) using the hybridization buffer 
and control provided by the manufacturer (Affymetrix Inc.). GeneChip Fluidics station 400 
(Affymetrix Inc.) was used to wash and stain the arrays. The standard protocol suggested by the 
manufacturer was used to detect the hybridized biotinylated cRNA. The chips were then 
scanned with a specific scanner (Affymetrix Inc.) to generate digitized image data (DAT) files. 
 
 
 
Microarray data analysis. 
DAT files generated for the four prototypic situations under analysis (TAp63α wt without 
induction, TAp63α wt with induction, TAp63αQ540L without induction, TAp63αQ540L with 
induction) were analyzed by GCOS (Affymetrix, USA) to generate background-normalized 
image data (CEL files). The presence of hybridization/construction artefacts was evaluated with 
the fitPLM function (Bioconductor package affyPLM). The probes (PM) intensity distribution 
was evaluated using hist function (Bioconductor package affy). Only an array from the 
TAp63αQ540L with induction group was found characterized by a narrow distribution of the 
probe (PM) intensities and was discarded. 
Probe set intensities were obtained by means of GCRMA, robust multiarray analysis method 
(Wu, Z and Irizarry, RA, Stochastic Models Inspired by Hybridization Theory for Short 
Oligonucleotide Arrays Proceedings of RECOMB 2004 
http://www.biostat.jhsph.edu/~ririzarr/papers/p177-irizarry.pdf). The full data set was 
normalized according to quantiles method (Bolstad, Irizarry et al. 2003). The hug133plus2 
54675 probe sets were filtered to have an interquantile range (IQR) for each probe set greater 
then 0.25 (A. von Heydebreck, W. Huber, and R. Gentleman Differential Expression with the 
Bioconductor Project, In Bioconductor projects working papers June 18, 2004). This filtering 
yielded 11857. Subsequently, “Significant analysis of microarrays” (SAM) software (Tusher, 
Tibshirani et al. 2001) was used to identify probe sets differentially expressed between wt and 
mutant p63 isoforms. The identification of differentially expressed probe sets was initially done 
using the multi class method (900 permutations, 50 false significants). This test requires one 
user-set parameter: a threshold value that can be adjusted to maximize the number of 
significant genes while minimizing the predicted false discovery rate. This analysis produced a 
total of 4000 differentially expressed probe sets. Subsequently, probe sets were filtered in order 
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to select only those characterized by a fold change≥|2| between not induced and induced cell 
lines in wt or mutant experiments. This filtering yielded a total of 100 probe set ids (Additional 
information table A). 87 out of 100 probe sets were associated to 81 Entrez Gene identifiers 
(gene ID; Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information 
at NCBI. Nucleic Acids Res. 2005, 33 Database Issue:D54-8.) and the remaining 13 
Affymetrix ids were not assigned to any gene ID. The IQR filtered data set was also analysed 
using the SAM two class unpaired method (Tusher, Tibshirani et al. 2001), to highlight probe 
set transactivated only by the wt or mutant isoforms. This test requires two user-set parameters: 
a minimal fold change value and a threshold value that can be adjusted to maximize the number 
of significant genes while minimizing the predicted false discovery rate. We conducted a 
blocked, two-class unpaired test using a 2-fold-change cut-off and a threshold allowing a false 
significant number about 1. This analysis produced a total of 18 differentially expressed probe 
sets for TAp63α wt (16 up-modulated and 2 down-modulated) and a total of 7 probe sets for 
the Q540L mutant isoform (1 up-modulated and 6 down-modulated) (Fig. 1, additional 
information table B). Probe sets found differentially expressed using the two class unpaired 
method were all included in set identified as differentially expressed with the multi class 
method. Since a certain amount of leaking of the tet-ON system was observed in our 
experiments (data not shown), it is possible that differential expression between not induced 
and induced cell lines might be under-estimated. Therefore, a two class unpaired test (2-fold-
change cut-off and false significant number about 1) between induced wt and mutant cell lines 
was also performed. The differentially expressed probe set were 441 (Additional information 
table C).  
To generate a robust set of differentially expressed genes to be further investigated the 
intersection between the 100 probe sets derived from the multi class analysis and the 441 probe 
sets derived by the two class analysis was selected. This intersection contains 45 probe sets 
linked to 36 annotated genes and 7 unmapped est  (fig. 3).  
The search of over expressed geneontology Biological Process themes was performed using 
Bioconductor GOstats package (Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, 
Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry 
R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang 
JY, Zhang J. Bioconductor: open software development for computational biology and 
bioinformatics. Genome Biol. 2004;5:R80.). Gene annotation was performed using 
Bioconductor annaffy library and hgu133plus2 annotation package (version 1.6.8). 
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Real-time RT quantitative PCR expression validation: 
Total RNA was reverse transcribed to cDNA with the Omniscript RT Kit following the 
manufacturer’s instructions (QIAGEN GmbH, Hilden, Germany, EUROPE). The primer 
sequences are shown in Table II. Primers were designed using the sequence identified by the 
Affymetrix identifier and Primer Express 2.0 software (Applied Biosystems, Foster City, CA, 
USA). Real-time quantitative PCR, 20 ul contained 2 ul of the cDNA, 1X SYBR GREEN PCR 
Master Mix (PE Applied Biosystems, Foster City, CA, USA) and 150 mM of each primers 
were performed with an ABI PRISM 7900HT Sequence Detection System using the following 
cycle conditions: 50°C for 2 min , 95°C for 10 min. , and 95°C for 15 s followed by 60°C for 1 
min 40 cycles. 384 plates were assembled by QIAGEN 8000 BIOROBOT (QIAGEN GmbH, 
Hilden, Germany, EUROPE). Negative cDNA controls (no cDNA) were cycled in parallel with 
each run. Fluorescence data were analyzed by the SDS 2.1 software (Applied Biosystems, 
Foster City, CA, USA) and expressing as Ct, the number of cycles needed to generate a 
fluorescent signal above a predefined threshold. Target gene mRNA levels were expressed as 2-
DCt, normalized for ACTB and POL2B, and fold changes were evaluate as 2-DDCt using as 
calibrator the non induced corresponding cell line, according to Livak and Schmittgen. (Livak 
and Schmittgen 2001). 
 
Formaldehyde Cross-linking and Chromatin Immunoprecipitation. 
H1299 ( 1x106 in 100mm) cell line were transfected with 5µg of  TAp63α encoding plasmid or 
5µg of pcDNA3-p53, alone or togheter with 5µg  HA-p14ARF expression plasmid. For ChIP 
assay with p63α wild type and mutant Q540L, H1299 cell line ( 1x106 in 100mm) were 
transfected with 5µg TAp63α encoding plasmid or 5µg of TAp63αQ540Lexpression plasmid. 
24 hours after transfection DNA and proteins were cross-linked by the addition of 
formaldehyde ( 1% final concentration) 10 min at RT before harvesting, and cross-linking was 
stopped by the addition of glycine pH 2.5 ( 125µM final concentration) for 5 min at RT. Cells 
were scraped off the plates, resuspended in hypotonic buffer for 5min in ice. Nuclei were spun 
down, resuspended in 400µl of SDS lysis buffer ( 1% SDS, 10mM EDTA, 50mM Tris-HCl 
pH8, and a protease-inhibitor mixture), ans sonicated to generate 500-2000 bp fragments. After 
centrifugation, the cleared supernatant was diluited 10-fold with immunoprecipitation buffer (  
50mM Tris-HCl pH8, 150mM NaCl, 5mM EDTA, 0,5% Nonidet P-40). The cell lysate was 
precleared by incubation at 4 °C with 20µl of protein-A beads preadsorbed with Salmon 
Sperma-DNA. The  cleared lysate were incubated overnightwith anti-p63 4A4 antibody ( Santa 
Cruz)  anti-p53 DO1 or without any antibody. Immunocomplex were precipitated with 30µl of 
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protein A beads preadsorbed with salmon sperma sonicated DNA. After centrifugation the 
beads were washed and the antigen was elueted with 2% SDS in Tris EDTA. DNA-protein 
cross-links were reversed by heating at 65 °C ON, and DNA was phenol-extracted and ethanol-
precipitated. Fragmented DNA was analyzed with the following primers : 
 p21/WAF: (F) 5’ CGTGGTGGTGGTGAGCTAGA          (R)  5’  CTGTCTGCACCTTCGCTCCT ,  
JAG 2      : ( F) 5’ CAAGTGGTGAACAAGGGAGACT    (R) 5’ ACTGCTGCCTTCTGGAAACTC 
Dlx3         : (F) 5’ AGAGAGGCGGAAGAGACGAG        (R)  5’ GAGGAGGGAGGAGAGAAGGA       
IKK          :(F)  5’ GCAGGAGTCATGGGAGAAAA         (R)  5’ TTTATTTGAAGCAAAGGGAGA 
 
 
 
Decay Rate Analysis 
 Saos2 cells (2.5 x105 in 35 mm) were transfected with ∆Np63α expression vector (0,2 µg) alone or 
along with pcDNA Dlx3-Flag (1µg). 18 hrs after transfection, cycloheximide (Sigma) was added to 
the medium at a final concentration of 40 µg/ml. Cells were harvested at the indicated time points. 
Total cell extracts were prepared as described above. 10 µg of cell extract was subjected to Western 
Blot and probed with anti-p63 and anti-FLAG antibodies and, as control, with anti-actin as a 
control. 
 
 
RT-PCR  
Saos-2 cells were transfected with a fixed amount of ∆Np63α expression vector 0.2 µg alone or 
with increasing amount of pcDNA Dlx3-Flag 1 and 1.5 µg. Total RNA was isolated using the RNA 
Extraction Kit (Quiagen). 1µg of total RNA was used to generate cDNA from each sample using 
one-step RT-PCR Kit (InVitrogen). Reverse-transcripts were amplified with the following p63 
specifi-primers primers:   
(F) 5’CCACAGTACACGAACCTGGGG                                  (R) 5’ CCGGGTAATCTGTGTTGGAG 
As an internal loading control we amplified a region from HPRT gene using the following primers: 
(F)  5’ CCTGCTGGATTACATTAAAGC                                  (R) 5’ CTTCGTGGGGTCCTTTTC 
PCR products were resolved by 2% agarose electrophoresis. RT-PCR amplification results were 
analyzed by Quantity One software ( Biorad). 
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Report  
The Hay Wells Syndrome-Derived TAp63αQ540L Mutant Has Impaired
Transcriptional and Cell Growth Regulatory Activity
ABSTRACT
p63 mutations have been associated with several human hereditary disorders charac-
terized by ectodermal dysplasia such as EEC (ectrodactyly, ectodermal dysplasia, clefting)
syndrome, ADULT (acro, dermato, ungual, lacrimal, tooth) syndrome and AEC (ankyloble-
pharon, ectodermal dysplasia, clefting) syndrome (also called Hay-Wells syndrome). The
location and functional effects of the mutations that underlie these syndromes reveal a
striking genotype-phenotype correlation. Unlike EEC and ADULT that result from missense
mutations in the DNA-binding domain of p63, AEC is solely caused by missense mutations
in the SAM domain of p63. In this paper we report a study on the TAp63α isoform, the
first to be expressed during development of the embryonic epithelia, and on its naturally
occurring Q540L mutant derived from an AEC patient. To assess the effects of the Q540L
mutation, we generated stable cell lines expressing TAp63α wt, ∆Np63α or the TAp63α-
Q540L mutant protein and used them to systematically compare the cell growth regulatory
activity of the mutant and wt p63 proteins and to generate, by microarray analysis, a
comprehensive profile of differential gene expression. We found that the Q540L substitution
impairs the transcriptional activity of TAp63α and causes misregulation of genes involved
in the control of cell growth and epidermal differentiation.
INTRODUCTION
The p63 protein is a transcription factor homolog of the p53 tumor suppressor. Unlike
p53, p63 functions primarily in epidermal-mesenchymal development during embryoge-
nesis. Mice in which p63 was inactivated displayed a fundamental defect in epithelial
lineage development and failed to develop stratified epithelia and epithelial appendages,
such as teeth, hair follicles and mammary glands.1,2 The role of p63 in the development
and differentiation of stratified epithelia, remains controversial. Indeed, recent studies
indicate that p63 may act as a molecular switch required for initiation of epithelial strati-
fication, or for maintaining the proliferative potential of basal keratinocytes in the mature
epidermis.3-5 It also seems to play a substantial role in the induction of apoptosis and
chemosensitivity.6-8
The p63 gene displays a high sequence and structural homology to p53.9 Like p53, the
p63 protein contains a transcriptional activator domain (TA) to induce transcription of
target genes, a DNA-binding (DB) domain and an oligomerization domain (OD), used
to form tetramers.10 In contrast to p53, multiple protein products are produced by the
p63 gene. Two promoters are present at the 5' end of the gene. The first produces TA-p63
proteins, while transcription from the second creates ∆N-p63 products lacking the
aminoterminal TA domain. In addition three alternative splicing routes at the 3' end gen-
erate proteins with different C-termini, denoted α, β and γ. The TA and ∆Np63α isoforms
alone contain a Sterile Alpha Motif (SAM) domain absent in p53: this is the most remarkable
structural difference between p63 and p53. This domain is a 65–70 amino acid residue
sequence found in many proteins, from yeast to human, whose functions range from signal
transduction to transcriptional repression.11 It is a protein-protein interaction domain also
found in p73, another member of the p53 gene family, as well as in other developmentally
important proteins, such as several Eph receptor tyrosine kinases.12 Recent studies have
identified a transcriptional inhibitory (TI) domain located between the SAM domain and
the C-terminus of p63α isoforms that is believed to be responsible for the lack of transac-
tivation ability of TAα compared to TAβ and γ on several different p53 target promoters.13
The analysis of the functions of the multiple p63 isotypes are complicated by the existence
of several mechanisms regulating their expression levels. Such mechanisms are still under
investigation.14-19
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A broad spectrum of mutations found in several ectodermal,
craniofacial and limb syndromes, namely EEC (ectrodactyly,
ectodermal dysplasia, clefting), AEC (ankyloblepharon, ectodermal
dysplasia, clefting), LMS (limb-mammary syndrome), ADULT
(acro-dermato-ungual-lacrimal-tooth) and SHFM (split-hand/split-foot
malformation) have been mapped in distinct p63 domains.20
The location of mutations in the p63 protein domains and their
functional implications reveal a striking genotype-phenotype corre-
lation: EEC and ADULT result from missense mutations in the DB
domain and SHFM from mutations in either the DB or the C-ter-
minal domain,21 whereas AEC is solely caused by missense mutations
in the SAM domain. Unlike the other ectodermal dysplasia syndromes,
AEC does not comprise ectrodactyly or other major limb defects,
but has ankyloblepharon and severe scalp dermatitis as its distin-
guishing features.22
A p63 SAM-domain model structure has been used to divide the
naturally occurring AEC mutations into in two groups. The first
(L518V, I541T, C526W) includes mutations in amino acids that are
predicted to be buried inside the protein and are believed to affect
its overall structure and stability. The second (G534V, T537P and
Q540L), whose direct effect on the protein is less obvious, contains
all the other amino acids that have a larger solvent accessible surface
and are not predicted to cause gross conformational changes.22 These
AEC mutations may disrupt the structural integrity of the SAM
domain or interfere with particular protein-protein interactions.12
They have, in fact, already been shown to disrupt the interaction of
p63 with the Apobec-1 binding protein-1(ABPP1)23 and thus alter
the splicing mechanism of fibroblast growth factor receptor-2,
FGFR2.11
Here, we report data from a study on the TAp63α isoform, which
is the first to be expressed during the development of embryonic
epithelia,3 and on the AEC-derived TAp63αQ540L (1607 A to T)
mutant protein. This was described by Hay and Wells in their case
no. 5.24 It is located within exon 13 and is predicted do not destroy
the overall structure of the SAM domain.22
To study the effects of the Q540L mutation on p63 functions we
generated stable cell lines that express wild-type (wt) TAp63α,
∆Np63α or the TAp63αQ540L mutant under the control of a
TET-inducible promoter and used them to compare the effects of
the mutant and wt p63 proteins on cell proliferation and generate,
by microarray analysis, a comprehensive profile of differential gene
expression. We found that the Q540L substitution affects the tran-
scriptional activity of TAp63α and causes misregulation of genes
involved in the control of cell growth and epidermal differentiation.
MATERIALS AND METHODS
Plasmids. Wt p63α in pcDNA3-His expression vector has been
described.15 Mutation Q540L was created by PCR, using the NdeI site-
containing upstream primer, p63NdeI_FW (CCA TCT TCA TAT GGT
AAC AGC TCC CCA CCT C) and the downstream primer p63NcoI_RW
(ATC ATC CAT GGA GTA ATG CTC AAT CAG ATA GA) containing
the NcoI site and the substitution A → T that introduces the mutation. The
mutated fragment was replaced in the TAp63α wt sequence,15 digested with
NdeI/NcoI to generate the TAp63αQ540L sequence and then cloned in
pcDNA3.
To create the plasmids encoding the p63 proteins under the control of
the rtTA responsive promoter, the cDNA fragments were extracted from
pcDNA using Hind III and Xba I, blunted and cloned into the pBIG-βgal
Not I site. The pTet-On, pTK-Hyg, and pBIG-βgal constructs were provided
by Clontech. The Bp100CAT and p21/WAF/CAT reporter plasmids have
already been described.15,25
Cells, transfection and reporter assays. Human lung carcinoma H1299
cells (p53 null, no p63 expression) were obtained from the American Tissue
Culture Collection and grown at 37˚C in humidified 5% CO2 in DMEM
supplemented with 10% fetal calf serum. H1299 cells (5 x 104) were plated
and transfected by calcium-phosphate precipitation with 20 µg of pTet-On
plasmid (Clontech). Fourty-eight hours later, the cells were selected by
adding G418 (100 µg/ml) to the medium. After four weeks, single
G418-resistant clones (H1299-rtTA) were picked up and expanded. The
presence of the rtTA regulator in these clones was checked by performing a
β-galactosidase assay on H1299-rtTA cell extracts after transient transfection
with the pBGI-βgal empty construct, with or without doxycycline (Sigma-
Aldrich) (1 µg/ml).
Tet-On/TAp63α, Tet-On/∆Np63β, Tet-On/TAp63αQ540L cell lines
were produced as follows:
7 x 104 H1299-rtTA cells were cotransfected with each of the pBIG-p63
constructs and the pTK-Hygro vector (20 to 1 rate) by calcium-phosphate
precipitation. Twenty-four hours later, each 100 mm plate was split (1:2)
and cells were selected by adding 800 µg/ml hygromycin (Sigma-Aldrich).
After 4 weeks, single hygro-resistant clones were picked up and expanded,
and their p63-inducible gene expression was determined by Western blot
and specific immunodetection. p63 stable clones were maintained in DMEM
supplemented with 10% Tet-Approved serum (Hyclone). CAT assays with
the WAFCAT or BP100CAT reporter plasmids were performed as previously
described.16
Growth rate determination. Approximately 6 x 104 cells were seeded in
60 mm-diameter plates in the presence or absence of doxycycline (1 µg/ml)
for five days to regulate exogenous protein expression. Medium was replaced
every 48 hrs. At the indicated time points, two plates were rinsed twice with
PBS to remove dead cells and debris. Live cells on the plates were trypsinized
and collected separately. Cells from each plate were counted three times in
a Burker chamber. The average number from two plates was used to deter-
mine the growth rate.
DNA histogram analysis. Cells were counted and seeded at 2 x 105/
100 mm plate with or without doxycycline (1 µg/ml). At the indicated time
points, live cells on the plates were trypsinized and both floating dead cells
in the medium and trypsinized live cells were centrifuged and washed twice
with PBS. Approximately 106 cells were incubated in 1 ml of 0.1% Na citrate,
50 µg/ml propidium iodide (Sigma Chemical Co., St. Louis, MO, USA),
20 µg/ml RNase A and 0.1% Nonidet P-40. Cells were incubated for 40' at
RT in a dark box. Stained cells were analysed in a fluorescence-activated
cytometer (FACSCalibur-BD, Menlo Park, CA, USA) within 1 hr. Data on
DNA cell-content were acquired with the CellQuest program (Beckton-
Dickinson) on 20,000 events at a rate of 150 ± 50 events/second and the
percentages of cells in the SubG1, G0–G1, S and G2–M phases were quan-
tified with the ModFit software (Beckton-Dickinson). The percentage of
dead cells/total cells was determined by trypan blue dye staining. Briefly,
aliquots of cells were mixed with an equal volume of 0.4% trypan blue dye
solution (Sigma Chemical Co., St. Louis, MO, USA) and incubated for 15'
at RT. Stained (dead) and unstained (live) cells were counted with a hemo-
cytometer and the percentage of dead cells/total cells was determined by
scoring an average of over 300 cells, twice per plate.
Subcellular immunolocalization assay. Immunolocalization was performed
on doxycycline (1 µg/ml) induced or uninduced Tet-On cells, 105 cells/ 35 mm
plate were grown on micro cover glasses (BDH). Fourty-eight hours later,
cells were washed with cold phosphate-buffered saline (PBS) and fixed with
4% paraformaldehyde (Sigma-Aldrich), for 15' at 4˚C. After a rinse with
PBS, fixed cells were permeabilized with ice-cold 0.1% Triton X-100 for 10'
and rinsed again with PBS. Cells were than incubated with DAPI
(4,6-diamidino-2-phenylindole; 10 mg/ml Sigma-Aldrich) for 3' and washed
again with PBS. Lastly, the glasses were mounted with Moviol (Sigma-
Aldrich) and cells were examined under a fluorescence microscope (Nikon).
To detect p63 protein the H137 (Santa Cruz) and the CyTM 3-conjugated
anti-rabbit IgG (ImmunoResearch Laboratories) antibodies were used at RT
for 30'. Images were digitally processed with Adobe Photoshop software.
Western immunoblot analysis. At the indicated time after transfection,
cells were lysed in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5%
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Nonidet-P40, 10 mM glycerol, 5 mM EDTA, 0.5% NaDOC and 1 mM
PMSF. Proteins were separated on 8% SDS-PAGE and blotted onto PVDF
membrane. Filters were incubated with the following primary antibodies
MDM2 (SC-965; Santa Cruz); p63 (H137; Santa Cruz); p63 (4A4; Santa
Cruz); anti-p21/WAF1 (Ab-11, CP74; Neomarkers), actin (1-19; Santa Cruz);
anti-goat IgG/HRP (Santa Cruz); anti-mouse IgG/HRP (Amersham);
anti-rabbit IgG/HRP (Bio-Rad).
EMSA. EMSA experiments were performed as already described.26 P63
proteins were translated in vitro by using TnT reticulocytes from Promega
with 0.5 µg of p63 plasmid DNA. Next, 10 µl of the individual reactions
was used for the binding reaction and for Western blot analysis. The probe
is a radiolabeled oligonucleotide duplex containing a p53-binding site present
in the p21 promoter (p21.1 described in ref. 27). A 100-fold molar excess
of the same cold oligonucleotide or an oligonucleotide containing a consensus
binding site for E2F1 were used for competition experiments. For the super-
shift anti-p63 antibodies (4A4; SantaCruz) or unrelated polyclonal anti-p21
antibodies (C-19; SantaCruz) were added to the sample prior to the binding
reaction (30' in ice).
Microarray sample preparation. Total RNA (ttlRNA) was extracted and
purified from stably transfected H1299 cell lines with the Concert
Cytoplasmic RNA Purification Reagent (Invitrogen, Carlsbad, CA), as sug-
gested by the manufacturer. ttlRNAs were then quantified and inspected
with a Bioanalyzer (Agilent Technologies). cRNAs were generated and
hybridized on 12 HGU133plus2 Affymetrix DNA chips according to the
Affymetrix protocol, ttlRNA (8 µg) was used to prepare double-stranded
cDNA with the one-cycle cDNA synthesis kit (Affymetrix, USA). The
cDNA was then used as a template to synthesize a biotinylated cRNA (16 hr,
37˚C) with the IVT kit (Affymetrix, USA). In vitro transcription products
were purified with the IVT cleanup module and approximately 35 µg of
cRNA were treated with the fragmentation buffer (35' at 94˚C). Affymetrix
12 HGU133plus2 array chips were hybridized with biotinylated cRNA
(20 µg/chip, 16 hr, 45˚C using the hybridization buffer and control provided
by the manufacturer (Affymetrix Inc.). GeneChip Fluidics station 400
(Affymetrix Inc.) was used to wash and stain the arrays. The standard protocol
suggested by the manufacturer was used to detect the hybridized biotinylated
cRNA. The chips were then scanned with a specific scanner (Affymetrix
Inc.) to generate digitized image data (DAT) files.
Microarray data analysis. DAT files generated for the four prototypic
situations (TAp63α wt without induction, TAp63α wt with induction,
TAp63αQ540L without induction, TAp63αQ540L with induction) were
analyzed by GCOS (Affymetrix, USA) to generate background-normalized
image data (CEL files). The presence of hybridization/construction artifacts
was evaluated with the fitPLM function (Bioconductor package affyPLM).
The probes (PM) intensity distribution was evaluated using hist function
(Bioconductor package affy). Only one array from the TAp63αQ540L
with induction group was characterized by a narrow distribution of PM
intensities and was discarded.
Probe set intensities were obtained by means of GCRMA, a robust
multiarray analysis method (http://www.biostat.jhsph.edu/~ririzarr/papers/
p177-irizarry.pdf ).28 The full data set was normalized according to the
quantiles method.29 The HGU133plus2 54675 probe sets were filtered to
provide an interquantile range (IQR) for each probe set greater then 0.25.30
This filtering yielded 11857. Subsequently, “Significant analysis of microar-
rays” software (SAM-software)31 was used to identify probe sets differentially
expressed between wt and mutant p63 isoforms. Differentially expressed
probe sets were initially identified with the multi class method (900 permu-
tations, 50 false significants). This test requires one user-set parameter: a
threshold value that can be adjusted to maximize the number of significant
genes while minimizing the predicted false discovery rate. This analysis
produced 4000 differentially expressed probe sets, which were then filtered
to select those characterized by a fold change ≥ |2| between not-induced and
induced cell lines in wt or mutant experiments. This filtering yielded 100
probe set ids (Additional information Table A): 87 were associated with 81
Entrez Gene identifiers (gene ID)32 and the remaining 13 probe sets were
not assigned to any gene ID. The IQR filtered data set was also analysed
with two-class unpaired method, implemented in the SAM-software,31 to
highlight probe sets transactivated only by the wt or mutant isoforms. This
test requires two user-set parameters: a minimal fold change value and a
threshold value that can be adjusted to maximize the number of significant
genes while minimizing the predicted false discovery rate. We conducted a
blocked, two-class unpaired test using a 2-fold-change cut-off and a threshold
allowing a false significant number of about 1. This analysis produced 18
differentially expressed probe sets for TAp63α wt (16 upmodulated and 2
downmodulated) and 7 probe sets for the Q540L mutant isoform (1
upmodulated and 6 downmodulated) (Fig. 1, additional information Table B).
All these 18 probe sets included in sets identified as differentially expressed
with the multi class method. Since a certain amount of leaking, at tran-
scriptional level, of the tet-ON system was observed in our experiments
(data not shown), differential expression between not-induced and induced
cell lines could have been underestimated. Therefore, a two-class unpaired
test (2-fold-change cut-off and false significant number about 1) between
induced wt and mutant cell lines was also performed. The differentially
expressed probe sets were 441 (Additional information Table C).
To generate a robust set of differentially expressed genes for further
investigation, the intersection between the 100 probe sets derived from the
multi class test and the 441 from the two-class test was selected. This inter-
section contains 45 probe sets linked to 36 annotated genes and 7 unmapped
est (Fig. 3).
Overexpressed Gene Ontology Biological Process themes were searched
with the Bioconductor GOstats package.33 Gene annotation was performed
by using the Bioconductor annaffy library and the HGU133plus2 annotation
package (version 1.6.8).
Real-time RT quantitative PCR (qPCR) expression validation. Total
RNA was reverse transcribed to cDNA with the Omniscript RT Kit following
the manufacturer’s instructions (QIAGEN GmbH, Hilden, Germany,
EUROPE). The primer sequences are shown in Table 1. Primers were
designed by using the sequence identified by the Affymetrix identifier and
Primer Express 2.0 software (Applied Biosystems, Foster City, CA, USA).
Real-time quantitative PCR, 20 µl contained 2 µl of the cDNA, 1X SYBR
GREEN PCR Master Mix (PE Applied Biosystems, Foster City, CA, USA)
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Figure 1. Expression of p63 isoforms in H1299 stable clones. Western blot
analysis for detection of the p63 protein expression levels in Dox-inducible
H1299 cells. Cells were harvested at the indicated time points after induc-
tion with 1 µg/ml doxycycline. Equal amounts of soluble lysates (30 µg)
from uninduced and induced clones expressing wild-type TAp63α, ∆Np63α
or the mutant TAp63αQ540L protein were evaluated for p63 protein levels
by Western blotting using an anti-p63 antibody (4A4; Santa Cruz
Biotechnology).
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and 150 µM of each primer were performed with an ABI PRISM 7900HT
Sequence Detection System in the following cycle conditions: 50°C for 2
min, 95°C for 10 min., and 95˚C for 15 s followed by 60°C for 1 min 40
cycles. 384 plates were assembled by QIAGEN 8000 BIOROBOT (QIA-
GEN GmbH, Hilden, Germany, EUROPE). Negative cDNA controls (no
cDNA) were cycled in parallel with each run. Fluorescence data were analyzed
with the SDS 2.1 software (Applied Biosystems, Foster City, CA, USA) and
expressed as Ct, the number of cycles needed to generate a fluorescent signal
above a predefined threshold. Target gene mRNA levels were expressed as
2-∆Ct, normalized for ACTB and POL2B, and fold changes were evaluates
as 2-∆∆Ct with the corresponding noninduced cell line as the calibrator
according to Livak and Schmittgen.34
Additional informations. Probe sets intensities and additional information
tables are available at http://www.bioinformatica.unito.it/bioinformatics/p63.
RESULTS
Production of TAp63α, TAp63αQ540L and ∆Np63α stable cell lines.
To investigate the effects of the Q540L mutation on p63 protein functions,
we generated stable H1299 cell lines, expressing TAp63α, ∆Np63α or
TAp63αQ540L, under a tetracycline/doxycycline (Dox)-inducible promoter
(see materials and methods). H1299 cells are p53 negative and show no
detectable levels of p63 and/or p73 (and data not shown).35
We first analysed by Western blot the timing and level of expression of
TAp63α wt, TAp63αQ540L and ∆Np63α proteins in our clones upon Dox
induction. Results from representative cell lines for TAp63α wt,
TAp63αQ540L and ∆Np63α are shown in Figure 1. Without Dox in the
medium, p63 proteins were undetectable. Addition of 1 µg/ml Dox led to
time-dependent induction of p63 proteins (Fig. 1). At 24 hrs of induction,
p63 proteins were already abundant and their expression levels were com-
parable as shown by immunodetection of actin as a loading control (data not
shown).
TAp63αQ540L is unable to induce a G1 cell cycle arrest. We first
decided to test the effects of wt TAp63α, ∆Np63α and mutant TAp63α-
Q540L protein on H1299 cell proliferation. TA and ∆Np63α were already
known to induce H1299 cell cycle arrest and apoptosis, though to a different
extent.35 According to these data, H1299 cells, expressing wt TAp63α or
∆Np63α showed a reduction of cell growth rate while non-induced cells
grew normally (Fig. 2A and B). The cell growth profile was completely
unaffected by TAp63αQ540L expression (Fig. 2C). The trypan blue dye
exclusion assay showed that TAp63α expression induced 9.2% of cell death
and ∆Np63α 3.4 % 72 hr after induction, whereas TAp63αQ540L had
completely lost this ability (Fig. 2D). Our p63-inducible clones were then
examined by flow cytometry. In a Dox-free culture medium, the three p63
stable cell lines and the parental H1299 cell lines maintained a similar cell
cycle phase distribution of DNA content (Fig. 2E and data not shown). At
48 hr, addition of 1 µg/ml of Dox resulted in G1 cell cycle arrest by both wt
TA and ∆Np63α with a parallel reduction in S and G2/M phases and a
significant increase of sub-G1 events (Fig. 2E). In contrast, when the
TAp63αQ540L mutant was induced, the percentage of cells in G1 phase
was unaffected and a slight increase in S phase with a corresponding decrease
in G2-M phase was observed (Fig. 2E).
Microarray and expression analysis. The finding that wt TAp63α inhibits
cell proliferation and induces cell death, whereas the TAp63αQ540L mutant
Figure 2. The Q540L amino acid substitution impairs the ability of wild-type TAp63α to induce a G1 cell cycle arrest and cell death. Cell growth profiles of
TAp63α (A), ∆Np63α (B) and TAp63αQ540L (C) stable cell lines under induced (+ Dox) or uninduced (- Dox) conditions. The growth rate was measured
as described in Materials and methods. (D) TAp63α, ∆Np63α and TAp63αQ540L stable clones, induced (+ Dox) or uninduced (- Dox) to express the respective
p63 proteins for 3 days, were analysed for the percentage of dead cells (blue cells/total cells) by trypan blue dye staining, as described in Materials and
methods. (E) DNA content distribution of TAp63α, ∆Np63α and TAp63αQ540L cells, expressing (+ Dox) or not (- Dox) the respective p63 proteins, analysed
for DNA content by propidium iodide staining of fixed cells. Data are the mean of three independent experiments. Standard deviations are also indicated.
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lacks these capabilities prompted us to generate a comprehensive profile of
differential gene expression by microarray analysis. Four prototypic situations
were evaluated: (a) TAp63α wt without induction (b) TAp63α wt with
induction (c) TAp63αQ540L without induction (d) TAp63αQ540L with
induction. The quality of the ttlRNA extracted from H1299 stable clones
was assayed by Bioanalyzer (Agilent). Three biological replicas generated for
all four situations were used to synthesize biotinylated cRNAs for hybridiza-
tion on 12 HGU133plus2 arrays containing 54675 probesets. Microarray
data show that there is a clear upmodulation of the wt and mutant p63α
proteins upon induction with doxycycline (Fig. 3, additional tables A and
B). Upmodulation of p63α was also confirmed by qPCR (data not shown).
A total of 45 probe set ids (Fig. 3) were identified as differentially expressed
and associated with 36 gene ids, whereas the other 7 have not been assigned.
QPCR validation was done for 11 out of 36 genes. Seven (Fig. 3, Y label)
showed a perfect overlap between microarray and qPCR data, both qualita-
tively and quantitatively (i.e., same trend and similar fold change variation),
three (Fig. 3, T label) were in agreement with microarray data, except that
the fold change variation was lower, and one (Fig. 3, N label) could not be
confirmed by qPCR.
A total of ten annotated genes transactivated upon induction of wt
TAp63α (Fig. 3D) did not respond to TAp63αQ540L. Four (GDF15,
TAp63αQ540L Transcriptional Regulatory Activity
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Table 1 Primers designed to validate microarray data 
by qPCR
ACTB_FW (Endogenous control) GAGTCCGGCCCCTCCAT
ACTB_RW (Endogenous control) GCAACTAAGTCATAGTCCGCCTAGA
ARX_FW CTCGGAGCGGCAGTGTTC
ARX_RW AAAAGAGCCTGCCGAATGC
BVES_FW GGCATCTCCAAATACATTGAAAGTC
BVES_RW CGTCTTGGTAACCTGAATTCTCTCT
CDKN1A_FW CAGCGACCTTCCTCATCCA
CDKN1A_RW GCTGCTAATCAAAGTGCAATGAA
CPM_FW TGGGATTCCAGAGTTCAAATACG
CPM_RW CAGCTCCCGCCCAACAG
CTCFL_FW TGTACTTTTTCATAATGCCCAGTGA
CTCFL_RW GAGGGTGGAAAAATCTTGTCAACT
FDXR_FW TGGATGTGCCAGGCCTCTAC
FDXR_RW TGGTTGTGGCTATGACACCTGTA
FGF5_FW GCCCAGAATCAGCCCTACAA
FGF5_RW GGAGGAAGGACAAGCTCATTCTT
GDF15_FW AAACATGCACGCGCAGATC
GDF15_RW CGGTCTTTTGAATGAGCACCAT
MDM2_FW ACCACCTCACAGATTCCAGCTT
MDM2_RW GCACCAACAGACTTTAATAACTTCAAA
PMAIP1_FW TGAACTTCCGGCAGAAACTTC
PMAIP1_RW GTTTTTGATGCAGTCAGGTTCCT
POLR2B_FW (Endogenous control) CCTGATCATAACCAGTCCCCTAGA
POLR2B_RW (Endogenous control) GTAAACTCCCATAGCCTGCTTACC
PTP4A1_FW CCCTAGCATTAATTGAAGGTGGAA
PTP4A1_RW CACGCCGCTTTTGTCTTATG
Figure 3. Microarray data clustering. Hierarchical clustering, (parameters:
Euclidean distance, average linkage clustering) was performed on average
log2 fold change variation between induced and not-induced TAp63α wt
and Q540L mutant stably transfected cell lines. (A) refers to genes which are
not significantly modulated upon induction of TAp63α wt and are instead
downmodulated by TAp63αQ540L expression. (B) includes only one gene
which is downmodulated by TAp63α wt expression and not significantly
modulated by TAp63αQ540L. (C) encloses genes not significantly modulated
upon induction of TAp63α wt, but upmodulated by TAp63αQ540L. (D)
refers to genes transactivated by TAp63α wt and characterized by a loss of
regulation by TAp63αQ540L.
                                        
CDKNIA/p21/WAF, MDM2, ARX) were
selected for qPCR to determine their responsive-
ness to TAp63α, ∆Np63α and TAp63αQ540L
(Fig. 4). GDF15 and CDKNIA-p21/WAF were
significantly transactivated by TAp63α only.
GDF15 was already activated at 12 hr of induc-
tion (Fig. 4A) and p21/WAF after 24 hr (Fig. 4B).
MDM2 and ARX were similarly transactivated
by wt TA and ∆Np63α (Fig. 4C and D), but none
of these four genes were modulated by TAp63α-
Q540L (Fig. 4A and D).
We also compared the transactivation poten-
tial of TAp63α, ∆Np63α and TAp63αQ540L
protein by CAT reporter assay in H1299 cells. A
fixed amount of p21/WAF promoter-CAT
construct was transiently transfected along with
increasing amounts of plasmids encoding p63α
proteins. As shown in Figure 5A, the Q540L
mutation strongly affects the ability of TAp63α
to induce the p21/WAF gene promoter, whereas
∆Np63α is a mild activator. Western blot analysis
of the protein lysates used in this assay demon-
strated that the mutant protein was expressed at
equal, if not greater, levels than wt TAp63α
These results suggest that the difference in activity
between wt and mutated TAp63α protein was
not due to differences in protein expression (data
not shown).
The microarray data showed no increase of
p21/WAF and MDM2 endogenous proteins in
TAp63αQ540L stable cells upon induction
(Fig. 5B). Moreover, the higher the expression
of TAp63αQ540L protein in our stable clone,
the lower was the level of endogenous p21/WAF
and MDM2 proteins compared to noninduced
cells (Fig. 5B). On the other hand, both wt
TAp63α and ∆Np63α enhanced p21/WAF and
MDM2 protein levels, though to a different extent
(Fig. 5B). The same results were obtained when these
experiments were repeated on two additional inde-
pendent TAp63αQ540L stable clones isolated during
our screening (data not shown).
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Figure 5. TAp63αQ540L has lost the ability to activate
p21/WAF and MDM2 gene expression. (A) H1299
were transiently transfected with 2 µg of p21/WAF-
CAT reporter plasmid/dish alone or with different
amounts of each p63-expressing plasmid (1, 2 or 3 µg).
After 48 h, cells were harvested, and CAT activity was
determined. The basal activity of the reporter was set
at 1. The data are presented as fold induction relative
to the sample without effector (white bar). Each
histogram bar represents the mean of triplicate assays
from three independent experiments. Standard
deviations are also indicated. (B) Western blot analysis
showing expression of TAp63α wt, A p63αQ540L
and ∆Np63α proteins in stable clones at 48 h upon
induction with the indicated amounts of doxycycline.
The expression of endogenous MDM2 and p21/WAF
proteins was also evaluated by specific immunodetec-
tion. MDM2 and p21/WAF protein levels increase in
parallel with TAp63α and ∆Np63α induction, but
decrease upon TAp63αQ540L induction. β-Actin was
used as a protein loading control.
Figure 4. QPCR data related to four genes transactivated by TAp63α wt and characterized by a loss of
control by the Q540L mutant. Gene expression was analyzed at 12 and 24 hours upon addition of
doxycycline to ∆Np63α, TAp63α and TAp63αQ540L inducible cell lines. Target gene mRNA levels
were normalized for ACTB (white bars) and POL2 (black bars) and expressed as -∆∆Ct (i.e., not-induced
cell line—induced cell line Cts).
A
B
                                                                                     
TAp63α and ∆Np63α proteins are solely located in the nucleus where
they act as transcriptional factors.16 The lack of transcriptional activity of the
TAp63αQ540L protein may stem from its inability to relocalate in the
nucleus. Inspection of the subcellular location of wt TAp63α and
TAp63αQ540L in our stable clones, by immunofluorescence showed that
both proteins were uniformly distributed in the nucleus with nucleolar
sparing. Therefore the Q540L amino acid substitution does not alter
TAp63α subcellular distribution (data not shown).
TAp63αQ540L binds to p21 promoter sequences in vitro and vivo and
interacts with SP1. The absolute inability of TAp63αQ540L to transactivate
the p21/WAF promoter prompted us to find out whether it can still bind to
the p53-consensus sequence of the p21/WAF promoter. We thus compared
the DNA binding capacity of wt and mutant TAp63α isoforms by an in
vitro DNA-binding assay. A radiolabeled duplex oligonucleotide representing
a p53-binding site previously identified in the p21/WAF promoter was used
as target DNA.16 Incubation of this oligonucleotide with in vitro translated
TAp63α or TAp63αQ540L mutant led to the formation of specific protein-
DNA complexes (Fig. 6A, lanes 2 and 6). The specificity of the TAp63-
DNA complexes was tested by a competition experiment: a 100-fold cold
molar excess of the oligonucleotide completely abolished the binding, while
an irrelevant control oligonucleotide had no effect (Fig. 6, lanes 3 and 4; 7
and 8). The identity of the TAp63α-DNA complexes was confirmed by a
supershift experiment (Fig. 6A, lanes 5 and 9) in which the in vitro translated
TAp63α proteins was incubated, prior to the binding reaction, with an anti-
body recognizing the p63 DNA-binding domain. Western blot analysis
showed that the relative abundance of these proteins was comparable (data
not shown). These observations indicate that wt TAp63α specifically binds
to a p53 consensus sequence of the p21/WAF promoter and that the Q540L
mutation does not affect this binding, at least in this in vitro assay.
The promoter of the human p21/WAF gene is characterized by a set of
six proximal Sp1 binding sites located in the proximal region (nucleotides
-120 to -40) and two distal p53 binding sites. These proximal sites have
been shown to be essential for the activation of p21/WAF promoter by
p53.36 Concerning the MDM2 gene promoter, a series of five consecutive
nnGGGGC repeats, bearing similarity to the Sp1 consensus, have been
identified (nucleotides -415 to -318). These conserved GC elements contribute
to the basal activity of the p53-inducible MDM2 promoter.37 Since it has
previously been reported that the γ isoform of TAp63α directly interacts
with Sp1, we decided to determine whether TAp63α is also able to interact
with Sp1 and, if so, the effect of the Q540L substitution. We performed
coimmunoprecipitation experiments in TAp63α and TAp63αQ540L
expressing cell lines, both Dox-induced and not. As shown in Figure 6B,
both wt and mutant TAp63α proteins were immunoprecipitated by a Sp1
polyclonal antibody. Reciprocal immunoprecipitation, which detects Sp1
protein with the p63 monoclonal antibody, did not immunoprecipitate Sp1
(data not shown).
DISCUSSION
Epithelial development and differentiation in embryo rely on a
set of temporally and spatially regulated molecular events. Recent
observations designate p63 as a driving force of this process: the
∆Np63α isoform maintains the proliferative potential of basal
keratinocytes in mature epidermis, whereas the TAp63α isoform,
which is the first to be expressed in mouse embryo, is believed to act
as a molecular switch required for commitment to epithelial stratifi-
cation.3 A broad spectrum of p63 mutations are responsible for
several human ectodermal, craniofacial and limb malformations.20
EEC and ADULT mutations are located in the DB domain of p63.
They abolish p63 DNA-binding and produce highly stable, but
transactivation-inert TAp63 proteins.38 AEC mutations are confined
to the SAM domain.22 Their effects on p63 transcriptional functions
are less predictable and they only affect the α isoforms.
The Q540L mutation impairs p63 transcriptional ability. Our
study provides evidence that the Q540L amino acid substitution
strongly impairs the transcriptional activity of TAp63α (Figs. 3 and 4).
Our genome-wide transcriptional profiles comparing the transcrip-
tional response induced by wt and TAp63αQ540L expression show
that 14 out of 45 differentially modulated probe sets (ten annotated
genes), are characterized by a loss of control (activation or repression)
by the Q540L mutant (Fig. 3D). As demonstrated (see Fig. 2, qPCR
and data not shown) the lack of transactivation ability of
TAp63αQ540L cannot be attributed to a decrease in its expression,
nor to alteration of its subcellular location. It is well documented
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Figure 6. TAp63αQ540L binds to p53 consensus site in the p21/WAF target promoter and associates with the Sp1 transcription factor. (A) The indicated
p63 proteins were in vitro translated by using TnT reticulocytes from Promega and 0.5 µ of each p63 plasmid DNA. Equal amounts of the individual
reactions were subjected to EMSA using a 32P-labeled oligo containing a p53-binding site present in the p21 promoter (p21.1 probe). Cold competition
was performed with either the 100-fold molar excess of the same oligonucleotide (lanes 3 and 7) or an oligonucleotide containing a consensus binding
site for E2F1 (lanes 4 and 8). For the supershift, anti-p63 antibodies (4A4; SantaCruz) were added to the sample prior to the binding reaction (lanes 5 and 9).
(B) Coimmunoprecipitation in TAp63α and TAp63αQ540L expressing cell lines. Both wt and mutant TAp63α proteins were immunoprecipitated by a Sp1
polyclonal antibody only upon their induction with doxycycline.
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that, p63, like p73, can bind to the p53 consensus DNA-binding
motif and activate a number of p53-regulated genes. In principle,
the Q540L mutation, even though it is predicted to not destroy the
overall structure of the SAM domain, could alter the DNA-binding
affinity of the mutant protein. As regulation of p21/WAF was
severely impaired in cells expressing the Q540L mutant, we tested
whether the mutant protein was still capable of interacting with a
p53-binding motif of the p21/WAF promoter. Our results indicate
that both wt TAp63α and its Q540L mutant are equally active in
binding to this sequence, at least in our in vitro system. On the other
hand, several data argue that particular coactivators expressed in
specific cell types and factors bound to the promoters confer speci-
ficity of gene regulation on the members of the p53 family and their
isoforms.39 For instance, ∆Np63α negatively regulates transcription
of the hsp70 promoter through its interaction with the CCAAT-
binding and NF-Y transcription factors,40 while Sp1 cooperates with
p53, p63 and p73 in synergistic transactivation of the p21/WAF
promoter.36 As a physical interaction between TAp63α and Sp1
takes place and is required for the regulation of EGFR gene expres-
sion,41 we determined whether TAp63α also interacts with Sp1 and,
if so, the effect of the Q540L substitution. Our data clearly indicate
that TAp63Q540L is still able to interact with Sp1 (Fig. 6B). Other
transcriptional factors may thus be crucial for p63-driven transcription
and the Q540L amino acid substitution may affect the interaction
between the p63 SAM domain and a still undefined factor.
Furthermore, we also found probe sets that are specifically up or
downregulated by the mutant protein alone (Fig. 3A and C). These
apparently conflicting results, too, may be a consequence of a loss of
transcriptional function, assuming that the above-mentioned genes
are p63 secondary targets repressed or activated by p63 primary targets.
Alternatively, the possibility that the Q540L aminoacid substitution
confers new transcriptional and cell growth regulating properties on
the TAp63α protein by altering its ability to interact with particular
coactivators or corepressors cannot be ruled out.
This possibility needs investigated by comparing the activity of
wt and mutant proteins directly on the promoters of these TAp63α-
Q540L-regulated genes by means of transient reporter assays.
Furthermore, other technologies, such as in vivo DNA-binding
assays and mass spectrometry, will aid in the identification of key
proteins involved in the regulation of p63’s transcriptional activities.
Differentially expressed genes and their implication in AEC
pathogenesis. An extensive search of the published literature to find
links between the physiological functions of the deregulated genes
and their role in AEC showed that, with the exception of p21/WAF
and MDM2, they were the subject of very few publications and little
was known about their functions. It was, however, found that GDF15,
BVES, CLMN and CPM are involved in the mechanisms of cell
differentiation,42-45 while ARX and FGF5 are associated with
embryonic development.46-49 GDF15 is the murine ortholog of the
human immunoregulatory cytokine macrophage inhibitory cytokine-1
(MIC-1) also known as PDF (prostate derived factor), a divergent
TGF-β superfamily member. It has proapoptotic and antimitotic
activities and is involved in the control of prostatic cell growth.44
Interestingly, the GDF15 promoter contains two putative p53
responsive elements and is upregulated by p53, though its expression
in response to injury also appears to be induced p53-independently.50,51
GDF15 seems to be a p63 target, specifically upregulated by
TAp63α (Fig. 4D). This regulation is completely abolished by the
Q540L amino acid substitution (Fig. 3D). The lack of GDF15
expression in epithelia may contribute to the abnormal differentiation
of epithelia-derived structures observed in AEC patients.
Another gene closely involved in development is ARX.47 Its
expression profile is highly complex and dynamic in the mouse
embryo brain, where it peaks at embryonic (E) day 9.5 just after the
TAp63α expression peak (E. 8.5).3 It is also a marker of adult neu-
ronal stem cells.47 Interestingly, both TAp63α and ARX transcripts
decrease at E 13.5, which corresponds to the switch from TAp63α
to ∆Np63α expression.3 Our transcriptional profiling combined
with the published data on ARX suggests that p63 and ARX may be
linked in a common regulatory pathway. The information available,
however, is not sufficient to allow a direct connection to be made
between the function of p63 and ARX in AEC.
Calmin (CLMN) is a protein with calponin homology (CH
domain) and transmembrane domains expressed in maturing sper-
matogenic cells. The cDNA encoding CLMN was isolated by RNA
differential display applied to developing mouse skin. The region
covering the CH domain showed a high level of homology with
β-spectrin, α-actinin, and dystrophin. The CLMN transcript was
detected in adult testis, liver, kidney, and large intestine; the expression
in testis was by far the strongest.42 CLMN is linked to skin develop-
ment. In mice, its mRNA starts to be detectable in the epidermis at
15.5–16.5 dpc (days post-coitum) and its expression increases as the
skin develops. The timing of CLMN gene expression corresponds to
the switch from the TA to the ∆N isoform. CLMN is only transacti-
vated by the Q540L mutant (Fig. 3C). Since induction of CLMN
expression fits in nicely with the timing of the switch from TAp63α
to ∆Np63α expression in the epithelial stratification program,3
TAp63α may be supposed to act as a transcriptional repressor of this
gene, with the result that expression of mutant TAp63α might
improperly anticipate CLMN expression during skin development.
BVES/Pop1 is the prototype of a new class of cell adhesion
molecules. It is expressed in the epithelial components of retina, lens
and cornea,52 during blood vessel development, in the gut endoderm
and the epicardium and in all three germ layers during avian organo-
genesis.53 BVES is transactivated by TAp63α and not modulated by
the Q540L mutant, and hence may be required to promote cell
adhesion and translocation during early embryogenesis.
Another interesting gene that is only transactivated by the mutant
p63 is SERPINH1, also known as HSP47. Hsp47 protein is involved
in skin wound regeneration and immunohistochemistry has demon-
strated Hsp47-positive cells in the epidermal cell layer of fetal and
neonatal rat skin. Hsp47 may be an important determinant of scar
formation, since scarless healing of fetal skin wounds correlates with
a lack of change in HSP47 expression.54
p21/WAF has long been known to arrest the cell cycle. In the
epithelium it is involved in maintenance of the stem cell compart-
ment:55 p21 null mice are unable to limit the production of stem
cells and their proliferative potential.55 p21/WAF is strongly transac-
tivated by the TAα wild-type isoform (Fig. 4A) and its promoter is
not or only mildly responsive to the ∆Nα isoform.27 By inducing
p21/WAF, TAp63α breaks the cell cycle by restraining stem cell
proliferation: the overall system is committed to the formation of
stratified epithelia. The parallel increase of ∆Nα and decrease of
TAp63α expression redirects the system to terminal differentiation.27
Our qPCR data (Fig. 4B) and expression studies (Figs. 3D and 5B)
support this scenario since the p21/WAF promoter is strongly
activated by the TAp63α wt isoform and p21/WAF upmodulation
is reduced if ∆Np63α is expressed. Interestingly, while ∆Np63α
seems less efficient than TAp63α as a p21/WAF activator (Figs. 4B
and 5B), they both induce a similar G1 cell cycle arrest. The
aminoterminal-deleted isoform should not be generally defined as a
www.landesbioscience.com Cell Cycle 85
TAp63αQ540L Transcriptional Regulatory Activity
                                                                             
transactivation-defective isoform. Our and other published data
indicate that ∆Np63α modulates transcription40 and this ability is
rather dependent on the specific gene promoter (see Fig. 4C and D).
In conclusion, the difference in the growth rate profiles (Fig. 2A and
B) of cells expressing either the TA or the ∆Np63α isoforms is likely
to be the result of the relatively higher efficiency of TAp63α with
respect to ∆Np63α in inducing cell death, as shown in Figure 2D.
The growth rate profiles and cell cycle distribution of cells
expressing the AEC-derived TAp63α protein are undistinguishable
from those of uninduced cells (Fig. 2C and E), indicating that the
Q540L amino acid substitution affects both the cell cycle arrest and
cell death inducing properties of p63. Finally, we suggest that dereg-
ulation of p21/WAF associated with the Q540L mutation will produce
a defect in the process of commitment to epithelial stratification that
simultaneously allows premature expression of skin differentiative
markers. A defect of this kind would explain the skin fragility and
chronic scalp erosions complicated by infections, which are a hallmark
of AEC. In conclusion, further investigation of the differentially
regulated genes identified in this study will result in a better under-
standing of the molecular mechanism underlying the AEC phenotype.
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